

SUBSTITUTE FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

06501-081001

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If Known, see 37 CFR 1.5)

09/831846

INTERNATIONAL APPLICATION NO.  
PCT/JP99/06449INTERNATIONAL FILING DATE  
18 November 1999PRIORITY DATE CLAIMED  
20 November 1998TITLE OF INVENTION  
NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN

APPLICANT(S) FOR DO/EO/US

Shin-ichi Funahashi, Shoji Miyata, Nobuo Nomura, Takahiro Nagase and Osamu Ohara

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 16 below concern other documents or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

**CERTIFICATE OF MAILING BY EXPRESS MAIL**Express Mail Label No. **EL228026564US**


I hereby certify under 37 CFR § 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 15, 2001

Date of Deposit

Signature

Typed Name of  
Person Signing

|  |              |   |  |  |               |                 |  |
|--|--------------|---|--|--|---------------|-----------------|--|
| J.S. APPLICATION NO. (if known)<br><b>097/831846</b>   |              | INTERNATIONAL APPLICATION NO.<br>PCT/JP99/06449 |  | ATTORNEY'S DOCKET NUMBER<br>06501-081001 |               |                 |  |
| 17. <input checked="" type="checkbox"/> The following fees are submitted:  |              |   |  | <b>CALCULATIONS PTO USE ONLY</b>         |               |                 |  |
| <b>Basic National Fee ( 37 CFR 1.492(a)(1)-( 5 ) ):</b><br><br>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1000</b><br><br>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860</b><br><br>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$710</b><br><br>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690</b><br><br>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100</b><br><br><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b> |              |   |  |  |               |                 |  |
|  |              |   |  |  |               | <b>\$860.00</b> |  |
|  |              |   |  |  |               | <b>\$0.00</b>   |  |
|  |              |   |  |  |               | <b>\$0.00</b>   |  |
|  |              |   |  |  |               | <b>\$0.00</b>   |  |
| Surcharge of <b>\$130</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).  |              |   |  | <b>\$0.00</b>                            |               |                 |  |
| Claims   | Number Filed | Number Extra                                    | Rate   |  |               |                 |  |
| Total Claims   | 9 - 20 =     | 0   | x \$18   | <b>\$0.00</b>                            |               |                 |  |
| Independent Claims   | 2 - 3 =      | 0   | x \$80   | <b>\$0.00</b>                            |               |                 |  |
| MULTIPLE DEPENDENT CLAIMS(S) (if applicable)   |              |   |  | + \$270                                  | <b>\$0.00</b> |                 |  |
| <b>TOTAL OF ABOVE CALCULATIONS =</b>   |              |   |  | <b>\$860.00</b>                          |               |                 |  |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.   |              |   |  | <b>\$0.00</b>                            |               |                 |  |
| <b>SUBTOTAL =</b>  |              |   |  | <b>\$860.00</b>                          |               |                 |  |
| Processing fee of <b>\$130</b> for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f))  |              |   |  | <b>\$0.00</b>                            |               |                 |  |
| <b>TOTAL NATIONAL FEE =</b>  |              |   |  | <b>\$860.00</b>                          |               |                 |  |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +  |              |   |  | <b>\$0.00</b>                            |               |                 |  |
| <b>TOTAL FEES ENCLOSED =</b>   |              |   |  | <b>\$860.00</b>                          |               |                 |  |
|  |              |   |  | <b>Amount to be refunded:</b>            | \$            |                 |  |
|  |              |   |  | <b>Charged:</b>                          | \$            |                 |  |
| a. <input checked="" type="checkbox"/> A check in the amount of \$860.00 to cover the above fees is enclosed.<br>b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.<br>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.  |              |   |  |  |               |                 |  |
| <b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.</b>  |              |   |  |  |               |                 |  |
| SEND ALL CORRESPONDENCE TO:  |              |   |  |  |               |                 |  |
| Janis K. Fraser, Ph.D., J.D.<br>FISH & RICHARDSON P.C.<br>225 Franklin Street<br>Boston, MA 02110-2804<br>(617) 542-5070 phone<br>(617) 542-8906 facsimile   |              |   | <br>SIGNATURE: |  |               |                 |  |
|  |              |   | NAME   |  |               |                 |  |
|  |              |   | Janis K. Fraser, Ph.D., J.D.   |  |               |                 |  |
|  |              |   | REGISTRATION NUMBER  |  |               |                 |  |
|  |              |   | 34,819   |  |               |                 |  |

09/831846  
JC18 Rec'd PCT/PTO 1 5 MAY 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shin-ichi Funahashi et al.      Art Unit : Unknown  
Serial No. :      Examiner : Unknown  
Filed : Herewith  
Title : NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN

**Box PCT**

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the claims:

Amend claims 3, 5, 7 and 8 as follows:

-- 3. A transformant carrying the DNA according to claim 1.

5. A method for producing a protein, said method comprising the steps of culturing the transformant according to claim 3 and recovering the expressed protein from said transformant or the culture supernatant thereof.

7. A method of screening for a compound which binds to a protein, said method comprising the steps of:

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL228026564US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit May 15, 2001

Signature

Joshua Cronin  
Typed or Printed Name of Person Signing Certificate

- (a) bringing the protein according to claim 4 into contact with a sample to be tested, and
- (b) selecting a compound having the activity to bind to the protein.

8. A method for detecting or measuring a protein, said method comprising bringing the antibody according to claim 6 into contact with a test sample, and detecting or measuring the formation of an immune complex of said antibody and a protein that specifically binds said antibody.--

REMARKS


Claims 1-9 are pending, claims 3, 5, 7 and 8 having been amended to delete multiple dependencies. No new matter has been added.

Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

May 15, 2001

  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

**Version with markings to show changes made**

In the claims:

Claims 3, 5, 7 and 8 have been amended as follows:

3. A transformant carrying the DNA according to claim 1 [or the vector according to claim 2].

5. A method for producing [the] a protein [according to claim 4], said method comprising the steps of culturing the transformant according to claim 3 and recovering the expressed protein from said transformant or the culture supernatant thereof.

7. A method of screening for a compound which binds to [the] a protein [according to claim 4], said method comprising the steps of:

(a) bringing the protein according to claim 4 into contact with a sample to be tested, and

(b) selecting a compound having the activity to bind to the protein [according to claim 4].

8. A method for detecting or measuring [the] a protein [according to claim 4], said method comprising bringing the antibody according to claim 6 into contact with a test sample [that apparently contains the protein according to claim 4], and detecting or measuring the formation of an immune complex of said antibody and [said] a protein that specifically binds said antibody.

3/PRTS

DESCRIPTION

NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN

5 Technical Field

The present invention relates to a novel membrane protein specifically expressed in the brain, a nucleic acid molecule encoding the protein, and methods of preparing and using same.

10 Background Art

A variety of cells present in the nerve system form a nerve network that supports high-level brain functions. Elucidation of mechanisms of differentiation, development and apoptosis of the nerve system is an important research subject, to deepen our understanding of functions of nerve system or critical mechanisms of nerve-related disorders. Thus, researches in this field have been energetically pursued.

Recently, a number of novel signal transducer molecules, including the PDZ protein, have been discovered one after another, as indicated by reports on the complex formation of receptors or ion channel molecules with the PDZ proteins such as PSD95/SAP90 in the post-synapse density (PSD) of postsynaptic membrane to perform the signal transduction (Science 269, 1737-1740 (1995), Nature 378, 85-88 (1995), Neuron 17, 103-113 (1996), Neuron 17, 255-265 (1996), J. Neurosci. 16, 2157-2163 (1996), Nature 386, 223, 239 (1997), TIBS 21, 455-458 (1996), J. Yanagisawa et al. (1997) J. Biol. Chem. 272, 7167-7172).

PDZ proteins are thought to serve as modular proteins in the formation of a protein complex, which transmits signals from outside to inside of cells and is as compact as possible. Thus, such proteins play an important role in the complex signal transduction of the nerve system.

On the other hand, glycoproteins present on the cell membrane are expected to function as the receptor to receive such external signals. Thus, there has been a high demand for the isolation and analysis of these membrane proteins for elucidating signal

transduction mechanisms in the brain.

#### Disclosure of the Invention

The present invention aims to provide a novel membrane protein  
5 which is specifically expressed in the brain, a nucleic acid molecule  
encoding the protein, and a method for manufacturing these compounds  
as well as the use thereof.

Present inventors have constructed a cDNA library of 4 kb or above  
in size from mRNA expressed in the human adult brain, and analyzed  
10 the structures of cDNAs contained in the library by the shotgun method,  
resulting in the successful isolation of a novel gene designated as  
"hh00149".

A protein encoded by the gene had a signal sequence comprising  
20 amino acids, a hydrophobic amino acid region which is thought to  
15 be a transmembrane domain, and further six binding sites for  
asparagine-bound sugar chain, indicating that this protein is one  
of transmembrane glycoproteins.

Northern blot analysis indicated that the hh00149 gene showed  
brain-specific expression. Furthermore, the hh00149 protein was  
20 found to have a typical PDZ protein-binding motif comprising  
"serine-threonine-valine" at its carboxyl end, indicating the  
presence of a PDZ protein as its binding protein. A variety of  
proteins have been hitherto known to bind to the PDZ protein,  
including the ion channel, glutamate receptor, tumorigenic  
25 transformation-related gene product, cell adhesion molecule,  
membrane-associated guanylate kinase, differentiation suppressing  
protein, etc. (Kornau, H.-C. et al. (1995) Science 269, 1737-1740;  
Kim, E. et al. (1995) Nature 378, 85-88, Matsumine et al. (1996)  
Science 272, 1020-1023, Axelrod, J. D., et al. (1996) Science 271,  
30 1826-1832, J. Yanagisawa et al., J. Biol. Chem. 272, 7167-7172 (1997),  
H. Dong et al. (1997) Nature 386, 279-284), participating in various  
signal transduction pathways.

From such tissue-specific expression of its gene and its  
structural characteristics, the hh00149 protein has been suggested  
35 to function as a signal transducer molecule from the outside to the  
inside of nerve cells.



This invention relates to a novel membrane protein specifically expressed in the brain, a nucleic acid molecule encoding the protein, and methods of preparing and using these compounds. More specifically, the invention provides the following:

5 (1) a DNA selected from the group consisting of the following (a) through (e):

(a) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2;

10 (b) a DNA comprising the coding region of the base sequence set forth in SEQ ID NO: 1;

(c) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2, which is modified by deletion and/or addition of one or more amino acid residues, and/or substitution with other amino acids, and functionally equivalent to the protein comprising the amino acid sequence set forth in SEQ ID NO: 2;

20 (d) a DNA hybridizing to the DNA comprising the base sequence set forth in SEQ ID NO: 1, and encoding a protein functionally equivalent to the protein comprising the amino acid sequence set forth in SEQ ID NO: 2; and

(e) a DNA comprising a DNA according to any of (a) through (d) and a DNA encoding other peptide or polypeptide, encoding a fusion protein;

(2) a vector inserted with the DNA according to (1);

25 (3) a transformant carrying the DNA according to (1) or the vector according to (2);

(4) a protein encoded by the DNA according to (1);

30 (5) a method for producing the protein according to (4), said method comprising the steps of culturing the transformant according to (3) and recovering the expressed protein from said transformant or the culture supernatant thereof;

(6) an antibody binding to the protein according to (4);

(7) a method of screening for a compound which binds to the protein according to (4), said method comprising the steps of:

35 (a) bringing the protein according to (4) into contact with a sample to be tested, and

(b) selecting a compound having the activity to bind to the protein according to (4);

(8) a method for detecting or measuring the protein according to (4), said method comprising the steps of bringing the antibody according to (6) into contact with a test sample that putatively contains the protein according to (4), and detecting or measuring the formation of an immune complex of said antibody with said protein; and

(9) a polynucleotide hybridizing to the DNA comprising the base sequence according to SEQ ID NO: 1 or a complementary strand thereof and having a chain length of at least 15 bases.

The base sequence of the hh00149 cDNA isolated by the present inventors is shown in SEQ ID NO: 1, and amino acid sequence of the hh00149 protein encoded by the cDNA is shown in SEQ ID NO: 2.

The hh00149 protein of this invention has a region of sequential hydrophobic amino acids, thought to be a signal sequence, in the amino terminal 20 amino acid residues, and another hydrophobic region, which is presumed to be a transmembrane domain, located about 2/3 from the amino terminal (cf. Example 6, Fig. 3), indicating that this protein is present as a transmembrane type protein on the cell membrane. In addition, the transcriptional product of the hh00149 gene has been brain-specifically detected (cf. Example 5, Fig. 2). These facts suggest that the hh00149 protein functions especially in the brain as a signal transducer molecule to transduce a signal from the outside to the inside of cells. Therefore, the hh00149 protein can be applied to the screening of novel signal transmitters, including nerve peptides, with an expectation of its utilization in the development of remedies and diagnostics for nerve-related disorders.

The present invention also includes proteins functionally equivalent to the above-described hh00149 protein. In this invention, the term "functionally equivalent" refers to those proteins having a biological activity equivalent to the hh00149 protein. It has been demonstrated, from the analysis of binding protein using the two-hybrid system, that the hh00149 protein binds to the "149Y2H#151" protein (Japanese Patent Application No. Hei 10-331701). Therefore, the biological activity of the hh00149 protein includes its binding

activity to the "149Y2H#151" protein. In addition, a binding sequence to the PDZ protein has been detected in the hh00149 protein, suggesting the presence of PDZ proteins capable of binding to the hh00149 protein. Therefore, the biological activity of the hh00149 protein also includes its binding activity to PDZ proteins. Binding activity between proteins can be detected using, for example, the following analytical methods, such as the immunoprecipitation method and two-hybrid system of yeast.

A method for inducing mutation into the amino acid sequence of protein can be used as the method for obtaining proteins functionally equivalent to the hh00149 protein. For example, a predetermined mutation can be induced into the amino acid sequence of a protein by the method of site-specific mutagenesis, using synthetic oligonucleotide primers (Kramer, W. and Fritz, H. J. Methods in Enzymol. (1987) 154, 350-367). Mutation in the amino acid sequence can also be induced using the site-specific mutagenesis system by PCR (GIBCO-BRL). It is possible, by these methods, to obtain proteins having the amino acid sequence of the hh00149 protein (SEQ ID NO: 2) which is modified by deletion or addition of one or a plurality of amino acid residues and/or substitution with other amino acid residues, without affecting its biological activity, and functionally equivalent to the hh00149 protein. Mutation of amino acids in proteins can also occur spontaneously. Such proteins, the amino acid sequence of which are artificially or spontaneously altered, are also included in the proteins of this invention.

Specifically, proteins functionally equivalent to the hh00149 protein are exemplified by those comprising the amino acid sequence set forth in SEQ ID NO: 2 from which one or more, preferably from two to thirty, more preferably from two to ten amino acid residues are deleted, or to which one or more, preferably from two to thirty, more preferably from two to ten amino acid residues are added, or in which one or more, preferably from two to thirty, more preferably from two to ten amino acid residues are substituted with other amino acids.

It is known that a protein having an amino acid sequence which is modified by deletion or addition of one or a plurality of amino

acid residues and/or substitution of one or a plurality of amino acid residues with other amino acids can still retain its original biological activity (Mark, D. F. et al., Proc. Natl. Acad. Sci. USA (1984) 81, 5662-5666, Zoller, M. J. & Smith, M. Nucleic Acids Research 5 (1982) 10, 6487-6500, Wang, A. et al., Science 224, 1431-1433, and Dalbadie-McFarland, G. et al., Proc. Natl. Acad. Sci. USA (1982) 79, 6409-6413).

A protein with one or a plurality of amino acid residues deleted is exemplified by, for example, the hh00149 protein in the form 10 deprived of its signal peptide. On the other hand, a protein with one or a plurality of amino acid residues added is exemplified by, for example, a fusion protein containing the hh00149 protein. A fusion protein in this case is a protein consisting of the hh00149 protein fused to other peptide or protein, and is included in this 15 invention. A fusion protein can be prepared using known techniques, by ligating the DNA encoding the hh00149 protein to another DNA encoding other peptide or protein so as to be in the same reading frame, transferring the chimeric DNA to an expression vector followed by expressing it in host cells. There is no particular limitation 20 in the type of other peptides or proteins used for the fusion to the protein of this invention.

For example, known peptides used for fusion include FLAG (Hopp, T. P. et al., BioTechnology (1988) 6, 1204-1210), 6x His comprising six histidine (His) residues, 10x His, influenza hemagglutinin (HA), 25 human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40T antigen fragment, lck tag,  $\alpha$ -tubulin fragment, B-tag, protein C fragment, etc. Proteins to be used include, for example, glutathione-S-transferase (GST), influenza hemagglutinin (HA), immunoglobulin constant region,  $\beta$ -galactosidase, MBP 30 (maltose-binding protein), etc.

The protein of this invention includes a protein which is encoded by a DNA hybridizing under stringent conditions to the DNA consisting of the base sequence set forth in SEQ ID NO: 1, and functionally equivalent to the hh00149 protein. Stringent hybridization 35 conditions can be appropriately selected by those skilled in the art, and are exemplified by, for example, low stringent conditions. Low

stringent conditions are, for example, at 42°C in 2x SSC and 0.1% SDS, and preferably at 50°C in 2x SSC and 0.1% SDS. More preferably, high stringent conditions may be selected, which are, for example, at 65°C in 2x SSC and 0.1% SDS. Under these conditions, as the  
5 hybridization temperature is elevated, DNA with a higher homology can be obtained.

Proteins which are functionally equivalent to the hh00149 protein, and are homologous to the protein (SEQ ID NO: 2) are also included in this invention. Herein, a "homologous protein" is one  
10 that has at least 70% or more, preferably at least 80% or more, more preferably at least 90% or more, and further more preferably at least 95% or more of amino acid sequence identity to that set forth in SEQ ID NO: 2. Sequence homology of proteins can be determined according to algorithm described in a literature (Wilbur, W. J. and Lipman,  
15 D. J. Proc. Natl. Acad. Sci. USA (1983) 80, 726-730).

The protein of this invention may be prepared by incorporating the DNA thus obtained into an expression vector, so as to be expressible under the regulation of the expression-regulating region, for example, enhancer/promoter. Then, host cells are transformed  
20 with this expression vector to express the protein.

More specifically, the process may be performed as follows. When mammalian cells are used, a commonly used useful promoter/enhancer, a DNA encoding the protein of this invention, a DNA to which the poly A signal is functionally linked downstream of the 3'-terminal of the  
25 above-described DNA or a vector containing these elements is constructed. A promoter/enhancer is exemplified by, for example, the human cytomegalovirus immediate early promoter/enhancer.

In addition, other promoter/enhancer usable for protein expression includes the viral promoter/enhancer of retrovirus, polyoma virus, adenovirus, simian virus 40 (SV40), and such, and a promoter/enhancer derived from mammalian cells, such as the human elongation factor 1 $\alpha$  (HEF1 $\alpha$ ).

For example, protein expression can be easily carried out according to the method of Mulligan et al. (Nature (1979) 277, 108)  
35 when the SV40 promoter/enhancer is used, or the method of Mizushima et al. (Nucleic Acids Res. (1990) 18, 5322) when the HEF1 $\alpha$

promoter/enhancer is employed.

When *E. coli* is used, proteins can be easily expressed by functionally ligating a commonly used useful promoter and signal sequence for the polypeptide secretion to a gene to be expressed. In this case, the promoter may be, for example, the lacZ promoter or the araB promoter. Protein expression may be achieved according to the method of Ward, et al. (Nature (1998) 341, 544-546; FASAB J. (1992) 6, 2422-2427) when the lacZ promoter is used, or the method of Better et al. (Science (1988) 240, 1041-1043) when the araB promoter is employed.

When a protein is to be produced in the periplasm of *E. coli*, the pelB signal sequence (Lei, S. P. et al., J. Bacteriol. (1987) 169, 4379) may be used as a protein secretion signal.

Replication origins derived from SV40, polyoma virus, adenovirus, bovine papilloma virus (BPV) and such, can also be used. Furthermore, to amplify the gene copy number in the host cell system, expression vectors may contain genes such as an aminoglycoside transferase (APH) gene, a thymidine kinase (TK) gene, a gene encoding xanthine-guanine phosphoribosyltransferase of *E. coli* (Ecogpt) and a dihydrofolate reductase (dhfr) gene, as selective markers.

Any expression vector may be used to produce the protein of this invention so long as they are preferably used in this invention. Expression vectors used in this invention include those derived from mammals such as pEF and pCDM8, (those derived) from insect cells such as pBacPAK8, (those derived) from plants such as pMH1 and pMH2, (those derived) from animal viruses such as pHSV, pMV and pAdexLcw, (those derived) from retroviruses such as pZIpneo, (those derived) from yeast such as pNV11 and SP-Q01, (those derived) from *Bacillus subtilis* such as pPL608 and pKTH50, and (those derived) from *E. coli* such as pQE, pGEAPP, pGEMEAPP and pMALp2.

Expression vectors of this invention constructed as described above are transferred to host cells using known methods, for example, the calcium phosphate method (Virology (1973) 52, 456-467), the electroporation method (EMBO J. (1982) 1, 841-845), and the like.

In this invention, any production systems can be used for the protein manufacturing. For the protein production, there are in

*vitro* and *in vivo* production systems. The *in vitro* production systems include those using eukaryotic cells and prokaryotic cells.

When eukaryotic cells are used, there are protein production systems using cells of animals, plants or fungi. Animal cells commonly used are mammalian cells, for example, CHO cell (J. Exp. Med. (1995) 108, 945), COS cell, myeloma cell, BHK (baby hamster kidney) cell, HeLa cell and Vero cell, amphibian cells, for example, oocytes of *Xenopus laevis* (Valle, et al., Nature (1981) 291, 358-340) or insect cells, for example, sf9, sf21 and Tn5 cells. Of CHO cells, especially those deficient of the DHFR gene, dhfr-CHO cell (Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) and CHO K-1 cell (Proc. Natl. Acad. Sci. USA (1968) 60, 1275), are preferably used.

Known plant cells used for protein production are those derived from *Nicotiana tabacum*, which can be cultured as callus. Fungus cells commonly used include yeast, belonging to, for example, the genus *Saccharomyces* such as *Saccharomyces cerevisiae*, and filamentous fungus of, for example, the genus *Aspergillus* such as *Aspergillus niger*.

When prokaryotic cells are used, there are systems using bacterial cells. *E. coli* and *Bacillus subtilis* are known bacterial cells.

Proteins can be obtained by transforming these cells with the desired DNA, and culturing the thus transformed cells *in vitro*. Cell culturing is performed according to known methods. DMEM, MEM, RPMI1640 and IMDM can be used as the culture medium. In this case, serum supplements, such as fetal calf serum (FCS), can be used together, or the culture may be performed in a serum-free medium. The pH during cultivation is preferably in the range of about 6 to 8. Culture is usually carried out at about 30 to 40°C for about 15 to 200 hr, with the exchange of medium, aeration and agitation as the occasion demands.

On the other hand, *in vivo* production systems include those using animals and plants. These animals or plants are transfected with a desired DNA to produce a protein in the body of animal or plant and the protein product is collected. "Host" in this invention includes these animals and plants.

When animals are used, there are production systems using mammals and insects. Goats, pigs, sheep, mice and cattle can be used as mammals (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). In addition, when mammals are used, transgenic animals can be also  
5 used.

For example, a desired DNA is inserted in the middle of a gene encoding a protein specifically produced in milk, such as the goat  $\beta$ -casein, to prepare a fusion gene. A DNA fragment containing this fusion gene inserted with the desired DNA is injected into a goat  
10 embryo, which is then implanted in the uterus of a female goat. The desired protein is obtained from the milk produced by the transgenic goat born from the goat which accepted the embryo or its offspring. To increase the yield of milk containing the protein produced by the transgenic goat, a suitable hormone may be appropriately  
15 administered to transgenic goats (Ebert, K. M. et al., Bio/Technology (1994) 12, 699-702).

In addition, insects, for example, silkworm can be used. In this case, silkworms are infected with the baculovirus inserted with a desired DNA, and the desired protein is obtained from their body fluid  
20 (Susumu, M. et al., Nature (1985) 315, 592-594).

Furthermore, when plants are used, tobacco, for example, can be employed. In the case of use of tobacco, a desired DNA is inserted into a plant expression vector, for example, pMON 530, and this vector is then transferred into a bacterium such as *Agrobacterium*  
25 *tumefaciens*. A tobacco plant, for example, *Nicotiana tabacum*, is infected with this bacterium, from leaves of which the desired protein is obtained (Julian, K. -C. Ma et al., Eur. J. Immunol. (1994) 24, 131-138).

Proteins of this invention thus obtained can be isolated from  
30 the inside and outside of cells or hosts, and purified to essentially pure and homogeneous protein preparations. Isolation and purification of proteins can be performed using conventional isolation and purification methods for usual proteins, and are not restricted in any way. For example, proteins can be isolated and  
35 purified by appropriate selection and combination of the following tools and techniques like chromatography column, filter,



ultrafiltration, salting-out, precipitation with solvent, extraction with solvent, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, etc.

5        Examples of chromatography include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, adsorption chromatography, etc. (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed. Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographies can be carried out using liquid phase chromatography, for example, HPLC, FPLC, etc. This invention also includes proteins highly purified using these purification methods.

15        The optional modification to the protein or the removal of partial peptide therefrom can be performed by reacting proteins before or after the purification with the appropriate protein modification enzyme. Trypsin, chymotrypsin, lysyl endopeptidase, protein kinase and glucosidase are commonly used protein modification enzymes.

20        This invention also includes partial peptides of the hh00149 protein (SEQ ID NO: 2). The partial peptides include, for example, those corresponding to the binding site for other proteins, such as the 149Y2H#151 protein and PDZ protein out of partial peptide sequences encoded by the hh00149 gene. These partial peptides can be used for the inhibition and so on of the signal transduction via the hh00149 protein.

30        Partial peptides of this invention can be prepared by genetic engineering techniques, known peptide synthesis method, or cleavage of the protein of this invention with a suitable peptidase. Peptide synthesis may be performed by either the solid phase or liquid phase synthesis method.

35        The present invention also relates to DNAs encoding the above-described proteins of this invention. DNAs of this invention are not only used for the production of proteins of this invention as described above but also may be applied to gene therapy, and such, for disorders caused by abnormalities of the gene encoding proteins

of this invention.

cDNAs encoding the proteins of this invention can be obtained, for example, by screening human cDNA libraries using the probes described in this specification.

5 Other cDNAs can be obtained from different cells, tissues, organs or species by further screening cDNA libraries with those cDNAs thus obtained or fragments thereof as probes. cDNA libraries may be prepared by the method described in, for example, Sambrook, J. et al., Molecular Cloning, Cold Spring Harbor Laboratory Press (1989),  
10 or commercially available DNA libraries may be used instead.

Furthermore, the sequencing of cDNA thus obtained enables the determination of the translation region encoded by the cDNA and the elucidation of amino acid sequence of the protein of this invention. In addition, the genomic DNA can be isolated by screening the genomic  
15 DNA library with cDNAs thus obtained as probes.

Specifically, the following procedures may be used. First, mRNA is isolated from cells, tissues or organs expressing the protein of this invention. For the isolation of mRNA, the total RNA is prepared by known methods, for example, the guanidine ultracentrifugation  
20 method (Chirgwin, J. M. et al., Biochemistry (1979) 18, 5294-5299), the AGPC method (Chomczynski, P. and Sacchi, N., Anal. Biochem. (1987) 162, 156-159), and such, and mRNA is then purified from the total RNA using an mRNA Purification Kit (Pharmacia), etc. mRNA can be also directly prepared using a QuickPrep mRNA Purification Kit  
25 (Pharmacia).

cDNA is synthesized from mRNA thus obtained using the reverse transcriptase. Synthesis of cDNA can also be performed using an AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Kogyo). cDNA can also be synthesized and amplified according to the  
30 5'-RACE method (Frohman, M. A. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 8998-9002; Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919-2932) using a 5'-Ampli FINDER RACE Kit (Clontech) and the polymerase chain reaction (PCR) with probes described in this specification.

35 The desired DNA fragments are prepared from PCR products thus obtained, and ligated to a vector DNA. Then, a recombinant vector

is prepared, transferred into *E. coli*, and such, and colonies are selected to prepare the desired recombinant vector. Base sequence of the desired DNA may be confirmed by known methods, for example, the dideoxynucleotide chain termination method.

5 Furthermore, the sequence for a higher expression efficiency can be designed for the DNA of this invention, considering the frequency of codon used by the host to be used for expression (Grantham, R. et al., *Nucleic Acids Research* (1981) 9, p43-74). DNAs of this invention can be modified using commercially available kits and known  
10 methods. For example, these modifications include the digestion with restriction enzymes, the insertion of synthetic oligonucleotides and suitable DNA fragments, the ligation of linkers, the insertion of the initiation codon (ATG) and/or termination codon (TAA, TGA or TAG), etc.

15 Specifically, the DNA of this invention includes DNAs encoding the protein comprising the amino acid sequence set forth in SEQ ID NO: 2 and mutants thereof described above. A preferred DNA comprises the base sequence extending from base 466 (A) to base 2832 (C) in the base sequence shown in SEQ ID NO: 1.

20 DNAs of this invention also include DNAs which hybridize under stringent conditions to the DNA consisting of the base sequence set forth in SEQ ID NO: 1, and encoding proteins functionally equivalent to the above-described proteins of this invention.

Stringent hybridization conditions can be appropriately  
25 selected by those skilled in the art, including, for example, low stringent conditions. Low stringent conditions refer to, for example, hybridization at 42°C and washing in 2x SSC and 0.1% SDS, and preferably at 50°C and in 2x SSC and 0.1% SDS. Yet more preferably, high stringent conditions may be selected. High stringent conditions  
30 refer to, for example, hybridization at 65°C and washing in 2x SSC and 0.1% SDS. Under these conditions, as the hybridization temperature is elevated, DNA with a higher homology can be obtained. The above-described DNAs to be hybridized are preferably cDNA or chromosomal DNA.

35 Proteins of this invention are useful for screening compounds binding to protein. That is, the proteins are used in the method

of screening for compounds that bind to the proteins of this invention, in which the method comprises bringing proteins of this invention into contact with a test sample that is expected to contain a compound to bind to the proteins and selecting a compound with the activity  
5 to bind to the proteins of this invention.

Proteins of this invention used in the screening may be any of recombinant, natural or partial peptides. Also they may be a purified protein, partial peptides thereof, or in the form of proteins expressed on the cell surface or membrane fractions.

10 Samples to be tested in the screening method of this invention may include, for example, peptides, purified or crude proteins, non-peptidic compounds, synthetic compounds, fermentation products of microorganisms, cell extracts, animal tissue extracts, marine creature extracts and plant extracts. Samples to be tested may be  
15 those naturally occurring or artificially synthesized.

Screening of proteins binding to the proteins of this invention can be carried out, for example, by the immunoprecipitation method. Specifically, the method can be carried out as follows. The gene encoding the protein of this invention is expressed by inserting the  
20 gene downstream of the promoter of foreign gene expression in pSV2neo, pCDNA I, pCD8, and such, and expressing the gene in animal cells, etc. Any generally used promoters may be employed for the expression, including the SV40 early promoter (Rigby In Williamson (ed.), Genetic Engineering, Vol. 3. Academic Press, London, p.83-141 (1982)), EF-1  
25  $\alpha$  promoter (Kim, et al. Gene 91, p. 217-223 (1990)), CAG promoter (Niwa, et al. Gene 108, p. 193-200 (1991)), RSV LTR promoter (Cullen, Methods in Enzymology 152, p.684-704 (1987)), SR  $\alpha$  promoter (Takebe et al., Mol. Cell. Biol. 8, p.466 (1988)), CMV immediate early promoter (Seed and Aruffo Proc. Natl. Acad. Sci. USA 84, p. 3365-3369  
30 (1987)), SV40 late promoter (Gheysen and Fiers J. Mol. Appl. Genet. 1, p.385-394 (1982)), Adenovirus late promoter (Kaufman et al., Mol. Cell. Biol. 9, p.946 (1989)), HSV TK promoter, etc. Transfer of a foreign gene into animal cells for its expression can be performed by any of the following methods, including the electroporation method  
35 (Chu, G. et al., Nucl. Acid Res. 15, 1311-1326 (1987)), the calcium phosphate method (Chen, C. and Okayama, H. Mol. Cell. Biol. 7,

2745-2752 (1987)), the DEAE dextran method (Lopata, M. A. et al. Nucl. Acids Res. 12, 5707-5717 (1984); Sussman, D. J. and Milman, G. Mol. Cell. Biol. 4, 1642-1643 (1985)), the lipofectin method (Derijard, B. Cell. 7, 1025-1037 (1994); Lamb, B. T. et al. Nature Genetics 5, 22-30 (1993)), Rabindran, S. K. et al. Science 259, 230-234 (1993)), etc. The protein of this invention can be expressed as a fusion protein having the recognition site for a monoclonal antibody by introducing the recognition site (epitope) for a monoclonal antibody, the specificity of which has been established, into the N- or C-terminal of the protein of this invention. For this purpose, a commercial epitope-antibody system can be utilized (Jikken Igaku (Experimental Medicine) 13, 85-90 (1995)). Vectors are commercially available which are capable of expressing fusion proteins with  $\beta$ -galactosidase, maltose-binding protein, glutathione S-transferase, green fluorescence protein (GFP), and such, via the multi-cloning site.

To minimize the alteration in properties of the protein of this invention due to the fusion protein formation, there has been reported a method for preparing a fusion protein by introducing only a small epitope portion comprising several to ten amino acid residues. For example, the epitopes of polyhistidine (His-tag), influenza hemagglutinin (HA), human c-myc, FLAG, Vesicular stomatitis virus glycoprotein (VSV-GP), T7 gene 10 protein (T7-tag), human herpes simplex virus glycoprotein (HSV-tag), E-tag (epitope on the monoclonal phage), and such, and monoclonal antibodies to recognize these epitopes can be utilized as the epitope-antibody system for screening proteins binding to the protein of this invention (Jikken Igaku (Experimental Medicine) 13, 85-90 (1995)).

In the immunoprecipitation, immune complexes are formed by adding these antibodies to the cell lysate prepared using suitable surfactants. This immune complex comprises a protein of this invention, a protein capable of binding to the protein, and an antibody. The immunoprecipitation can also be performed using an antibody to a protein of this invention besides antibodies to the above-described epitopes. An antibody to a protein of this invention can be prepared by inserting a gene encoding a protein of this

invention into an appropriate expression vector of *E. coli* to express it in the bacterium, purifying the protein thus expressed, and immunizing rabbits, mice, rats, goats, chicken, and such, with the purified protein. The antibody can also be prepared by immunizing  
5 the above-described animals with partial peptides of the protein of this invention.

Immune complexes can be precipitated using, for example, Protein A Sepharose and Protein G Sepharose in case that the antibody is a murine IgG antibody. In addition, in the case where the protein of  
10 this invention is prepared as a fusion protein with the epitope of, for example, GST, and such, the immune complex can be formed using a substance that specifically binds to these epitopes, such as glutathione-Sepharose 4B, and such, giving the same result as in the case where the antibody for the protein of this invention is used.

15 Immune precipitation, in general, may be carried out according to, or following the method described in the literature (Harlow, E. and Lane, D.: Antibodies, pp.511-552, Cold Spring Harbor Laboratory publications, New York (1988)).

SDS-PAGE is generally used for the analysis of  
20 immunoprecipitated proteins. Bound proteins can be analyzed based on the molecular weights of proteins using a gel of an appropriate concentration. In this case, although proteins bound to the protein of this invention, in general, are hardly detectable by the usual protein staining method, such as Coomassie staining and silver  
25 staining, the detection sensitivity can be improved by culturing cells in a medium containing the radio isotope-labeled <sup>35</sup>S-methionine and <sup>35</sup>S-cysteine to label proteins inside the cells, and detecting the labeled proteins. Once the molecular weight of the protein is determined, the desired protein can be purified directly from  
30 SDS-polyacrylamide gel and sequenced.

And, another embodiment of screening of this invention is exemplified by a method utilizing the 2-hybrid system using cells (Fields, S., and Sternglanz, R., Trends. Genet. (1994) 10, 286-292).

Herein, a 2-hybrid system can be used, in which (1) an expression  
35 vector containing a first DNA encoding a fusion protein, comprising the protein of this invention and one of the subunits of a

heterodimeric transcriptional regulatory factor, and (2) another expression vector containing a second DNA, comprising a desired cDNA as the test sample ligated to a DNA encoding another subunit of the heterodimeric transcriptional regulatory factor, is introduced into  
 5 cells, and expressed, so that when the protein encoded by the cDNA binds to the protein of this invention to allow the transcriptional regulatory factor to form a heterodimer, the reporter gene previously constructed within the cells is expressed. Alternatively, another 2-hybrid system can be used, in which a transcriptional regulatory  
 10 factor, such as the yeast GAL4 protein having a DNA-binding domain and a trans-activation domain, is separated by each domain, a first expression vector containing DNA encoding the fusion protein, comprising the DNA-binding domain of the transcriptional regulatory factor and the protein of this invention, and a second expression  
 15 vector, containing DNA comprising a desired cDNA as the test sample ligated to DNA encoding the trans-activation domain of the transcriptional regulatory factor, are introduced into cells and expressed, so that when the protein encoded by the cDNA binds to the protein of this invention to allow the transcriptional regulatory  
 20 factor to form a heterodimer, the reporter gene previously constructed within the cells is expressed. When there is a protein capable of binding to the protein of this invention, the protein can be sorted out by detecting or measuring the expression amount of the reporter gene.

25 More specifically, the process may be performed as follows. That is, DNA encoding the protein of this invention is ligated to the DNA encoding the DNA-binding domain of LexA, so that they are in the same reading frame to form a first expression vector. Next, a second expression vector is formed by ligating a desired cDNA to the gene  
 30 encoding the trans-activation domain of GAL4.

After the cells integrated with the HIS3 gene the transcription of which is regulated by the promoter having the LexA-binding motif are transformed with the above-described expression plasmids of the 2-hybrid system, they are incubated in a histidine-free synthetic  
 35 medium. In this case, cell growth is observed only when the interaction between proteins occurs. Thus, an increase in the

expression amount of reporter gene can be assessed by the growth extent of the transformant. Besides the HIS3 gene, the Ade2 gene, the LacZ gene, the CAT gene, the luciferase gene, and such, can be used as the reporter gene.

5       The 2-Hybrid system can be constructed using a conventional method, or using commercial kits instead. Commercially available 2-hybrid system kits include a MATCHMARKER Two-Hybrid System, Mammalian MATCHMAKER Two-Hybrid Assay Kit (both from CLONTECH), HybriZAP Two-Hybrid Vector System (Stratagene).

10       In fact, receptor-protein interactions involved in the ion channel and signal transduction having the PDZ domain have been demonstrated using the 2-bybrid system of yeast, including the binding of APC to hDLG (A. Matsumine et al. Science 272, 1020-1023 (1996)), the binding of GRIP to the AMPA receptor (H. Dong et al.  
15 Nature 386, 279-284 (1997)), the binding of Homer to the glutamate receptor (P. R. Brakeman et al. Nature 386, 284-288 (1997)), the binding of SRY to SIP-1 (F. Poulat et al. J. Biol. Chem. 272, 7167-7172 (1997)), etc.

      In addition, screening of proteins binding to the protein of this  
20 invention can be also performed using the West-western blotting method (Skolnik, E. Y. et al., Cell (1991) 65, 83-90). Namely, cDNA is isolated from cells, tissues and organs in which protein capable of binding to the protein of this invention is expected to be expressed, and transferred into a phage vector, for example,  $\phi$ gt11,  
25 ZAPII, and such, to prepare a cDNA library, which is then expressed on plates coated with a growth medium. The protein thus expressed is fixed on a filter, which is then reacted with the labeled, purified protein of this invention, and plaques expressing a protein bound to the protein of this invention can be detected by the label. Methods  
30 for labeling the protein of this invention include methods utilizing the binding activity of biotin and avidin, methods utilizing antibodies specifically binding to the protein of this invention, or peptides or polypeptides fused with the protein of this invention, methods utilizing the radioisotopes, methods utilizing fluorescence,  
35 etc.

      Screening for compounds which bind to the protein of this



invention can be also carried out using affinity chromatography. The protein of this invention is immobilized on the carrier in the affinity chromatography column, to which a test sample, which is expected to express a protein capable of binding to the protein of this invention, is applied. After applying the test sample, the column is washed, and protein which binds to the protein of this invention can be obtained.

Compounds isolated by the above-described screening method can be candidates for drugs to stimulate or suppress the activity of the protein of this invention in disorders caused by its functional abnormalities, etc. Compounds, which are obtained by the screening method of this invention and which have the activity to bind to the protein of this invention, the partial structure of which is modified by addition, deletion and/or substitution (of amino acid residues), are also included in compounds obtained by the screening method of this invention.

When compounds obtained using the screening method of this invention are used as drugs for humans and mammals, for example, mice, rats, guinea pigs, rabbits, chickens, cats, dogs, sheep, pigs, cattle, monkeys, baboons and chimpanzees, they can be administered according to commonly used means.

The compounds can be administered, as the occasion demands, orally, as sugar-coated tablets, capsules, elixirs and microcapsules, or parenterally, in the form of sterile solutions in water or other pharmaceutically acceptable liquids, or suspensions for injections. For example, drugs can be manufactured by mixing substances having the activity to bind to the protein of this invention with physiologically acceptable carriers, seasonings, excipients, vehicles, anticeptics, stabilizers and binders in the unit dosage form required in a generally accepted pharmaceutical procedure. Amounts of effective ingredients in these pharmaceutical preparations are adjusted so as to obtain the appropriate dose in the specified range.

Additives which can be mixed in tablets and capsules include, for example, binders such as gelatin, corn starch, tragacanth gum and arabic gum, excipients such as crystalline cellulose, bulking

agents such as corn starch, gelatin and alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose, lactose or saccharine, and flavors such as peppermint, *Gaultheria adeno-thrix* oil or cherry. When the dispensing unit form is a capsule, liquid  
 5 carriers, such as oil, can be further added to the above-described materials. Sterile compositions for injection can be prescribed using vehicles such as distilled water for injection according to standard pharmaceutical procedure.

Aqueous solutions for injections include, for example,  
 10 physiological saline and isotonic solutions containing glucose and other supplements such as D-sorbitol, D-mannose, D-mannitol, sodium chloride, and such, and suitable solubilizers, for example, alcohols, more specifically, ethanol, polyalcohols such as propylene glycol, polyethylene glycol, non-ionic surfactants such as polysorbate 80  
 15 (TM) and HCO-50 may be used together.

Oily solutions, including sesame oil and soybean oil, and benzyl benzoate and benzyl alcohol may be used together as the solubilizer. Injections may be combined with buffers such as phosphate buffer and sodium acetate buffer, soothing agents such as procaine  
 20 hydrochloride, stabilizers such as benzyl alcohol, phenols and antioxidants. Injections thus prepared are typically filled in suitable ampules.

Though they vary depending on the symptoms, doses of compounds having the activity to bind to the protein of this invention are in  
 25 the range of about 0.1 to 100 mg, preferably about 1.0 to 50 mg, and more preferably about 1.0 to 20 mg per day for adults (based on the body weight 60 kg) in the case of oral administration.

Though it varies depending on the subject to be administered, target organ, symptom and method of administration, a single dose  
 30 of the compounds for the parenteral administration is preferably administered, for example, when it is in the form of injection, intravenously to normal adults (based on the body weight 60 kg) in the range of about 0.01 to 30 mg, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg or thereabout per day. Doses  
 35 converted on the 60 kg body weight basis can be similarly administered to other animals.

Antibodies of this invention can be obtained as monoclonal or polyclonal antibodies by known means.

Antibodies specifically binding to the protein of this invention can be prepared by immunizing suitable animals with protein used as the antigen according to a usual immunization method, fusing immunocytes thus obtained with known parent cells by a usual cell fusion method, and screening antibody-producing cells by an ordinary screening method.

Specifically, monoclonal or polyclonal antibodies which specifically binds to the protein of this invention may be prepared as follows.

For example, the protein of this invention used as the antigen for obtaining antibodies, though there is no limitation in animal species from which it is derived, is preferably a protein derived from mammals, for example, humans, mice or rats, especially from humans, which can be obtained using the gene sequence or amino acid sequence disclosed in the present specification.

In this invention, proteins having the biological activities of the proteins described in this specification can be used as the antigen. Partial peptides of these proteins can be also used as the antigen. These partial peptides of the protein include, for example, the amino (N)-terminal fragments and carboxyl terminal (C) fragments of the protein. "Antibody" as described in this specification means an antibody specifically reacting with the full length protein or fragments thereof.

After inserting the gene encoding the protein of this invention or fragments thereof into a known expression vector and transforming host cells described in this specification with this recombinant vector, the desired protein or fragments thereof are obtained from inside and outside host cells or from host cells by a standard method. These proteins may be used as the antigen. Cells expressing the protein or the lysate thereof, or the chemically synthesized protein of this invention may also be used as the antigen.

Although there is no limitation in species of mammals to be immunized with the antigen, it is preferable to take into consideration the compatibility with parent cells used for cell

fusion, and animals of the rodent, lagomorph and primate are generally used.

For example, mice, rats, hamsters, and such, are used among the rodent animals, rabbits among lagomorph animals, and monkeys among  
5 primate animals. Among monkeys, catarrhine monkeys (old world monkeys), for example, *Macaca fascicularis*, rhesus monkey, baboon, chimpanzee and such are used.

Immunization of animals with antigens is carried out according to any known method. For example, immunization in general is  
10 performed by the intraperitoneal or subcutaneous injection of the antigen to mammals. Specifically, the antigen is diluted or suspended to the appropriate amount in PBS (Phosphate-Buffered Saline) or physiological saline, mixed with suitable amount of usual adjuvant, for example, Freund's complete adjuvant, as the occasion  
15 demands, emulsified, and then administered to mammals, favorably followed by several booster injections of the antigen mixed with an appropriate amount of Freund's incomplete adjuvant every 4~21 days. In addition, suitable carriers can be used at the time of immunization with the antigen. Elevation of levels of the desired antibody in  
20 the sera of animals thus immunized is confirmed by a standard method.

Herein, polyclonal antibodies to the protein of this invention are obtained by withdrawing the blood of mammals sensitized with the antigen after confirming the elevation of levels of desired antibody in the serum, and isolating the serum from the blood by a known method.  
25 Serum containing polyclonal antibody may be used as the polyclonal antibody, or fractions containing polyclonal antibody may be further isolated from the serum as the occasion demands.

Monoclonal antibodies can be obtained by removing immunocytes from the mammals, after confirming the elevation of levels of desired  
30 antibody in the serum of mammals sensitized with the above-described antigen, and subjecting them to cell fusion. In this case, immunocytes preferably used for cell fusion are spleen cells in particular. Parent cells to be fused to the above-described immunocytes are preferably mammalian myeloma cells, more preferably  
35 myeloma cells which have acquired characteristics for the selection of fused cells by drugs.

Cell fusion of the above-described immunocytes and myeloma cells can be carried out according to a known method, for example, the method of Milstein et al. (Galfre, G. and Milstein, C., *Methods Enzymol.* (1981) 73, 3-46), etc.

5       Hybridomas thus obtained by cell fusion are selected by culturing them in a standard selection medium, for example, the HAT culture medium (culture solution containing hypoxanthine, aminopterin and thymidine). Culturing in the HAT medium is continued for a sufficient time required for killing other cells (non-fused cells) than desired  
10   hybridomas, usually for several days to several weeks. Then, a usual limiting culture-dilution method is applied for carrying out screening and cloning of hybridomas producing the desired antibody.

In addition to the above-described hybridomas obtained by immunizing animals other than humans with the antigen, human  
15   lymphocytes, for example, human lymphocytes infected with the EB virus, are sensitized with a protein, protein expressing cells or lysates thereof *in vitro*, and the sensitized lymphocytes are fused with human-derived myeloma cells having a permanent proliferation potency, for example, U266 cells, to obtain hybridomas capable of  
20   producing the desired human antibody having the activity to bind to the protein (Unexamined Published Japanese Patent Application No. Sho 63-17688).

Furthermore, human antibodies against a protein may be obtained by immunizing transgenic animals having a repertoire of human  
25   antibody genes with an antigenic protein, cells expressing the protein or lysate thereof, to obtain antibody-producing cells, and fusing these cells to myeloma cells to prepare hybridomas, which are used to obtain human antibody against the protein (cf. International Patent Application Nos. WO92-03918, WO93-2227,  
30   WO94-02602, WO94-25585, WO96-33735 and WO96-34096).

Besides the production of antibody using hybridoma, immunocytes, such as sensitized lymphocytes, and such, producing antibody which is immortalized with oncogenes may be used for the antibody production.

35       Monoclonal antibodies thus obtained can be also prepared as a recombinant antibody, using genetic recombination techniques (cf.,

for example, Borrebaeck, C. A. K. and Larrick, J. W., THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). A recombinant antibody is produced by cloning DNA encoding the protein from hybridoma or immunocytes such as sensitized lymphocytes producing the antibody, incorporating the DNA into appropriate vector, and transferring the vector into host cells. This recombinant antibody is also included in this invention.

Antibodies of this invention may also include fragments and modified products of the antibody, so long as they are capable of binding to the protein of this invention. For example, the antibody fragments include Fab, F(ab')<sub>2</sub>, Fv or a single-chained Fv (scFv) prepared by linking the H-chain to the Fv of L-chain via a suitable linker (Huston, J. S. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 5879-5883). Specifically, antibody fragments are produced by digesting the antibody with enzymes, for example, papain or pepsin, or by constructing a gene encoding these fragments, inserting the gene into an expression vector, and expressing it in suitable host cells (cf., for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A. H., Methods Enzymol. (1989) 178, 476-496; Pluckthun, A. and Skerra, A., Methods Enzymol. (1989) 178, 497-515; Lamoyi, E., Methods Enzymol. (1986) 121, 652-663; Rousseaux, J. et al., Methods Enzymol. (1986) 121, 663-669; Bird, R. E. and Walker, B. W., Trends Biotechnol. (1991) 9, 132-137).

Antibody bound to various molecules, such as polyethylene glycol (PEG), and such, can be also used as the modified antibody. The "antibody" of this invention also includes these modified antibodies. These modified antibodies can be prepared by chemically modifying the antibody obtained as above. These modification methods have been already established in this field.

In addition, the antibody of this invention can be obtained, using known techniques, as a chimeric antibody comprising the variable region derived from a non-human antibody and the constant region derived from a human antibody, or a humanized antibody comprising the CDR (complementary-determining region) derived from a non-human antibody, the FR (framework region) and the constant region derived from a human antibody.

Antibodies obtained as described above can be purified to homogeneity. For the isolation and purification of the antibody used in this invention, any methods of isolation and purification used for ordinary proteins can be applied without limitation.

5 Concentration of the antibody obtained as described above can be determined by the measurement of absorbance or the enzyme-linked immunosorbent assay (ELISA), etc.

Furthermore, ELISA, EIA (enzyme immunoassay), RIA (radioimmunoassay) or fluorescent antibody technique can be used as  
10 the methods for measuring the antigen-binding activity of the antibody of this invention. For example, when ELISA is used, the protein of this invention is added to plates on which the antibody of this invention has been immobilized, and then a sample containing the desired antibody, for example, the culture supernatant of  
15 antibody-producing cells or purified antibody is added to the plates. A secondary antibody labeled with an enzyme, for example, alkaline phosphatase and such, to recognize the antibody is added to the plates. After incubating and washing the plates, the enzyme substrate such as p-nitrophenyl phosphate, and such, is added to measure the  
20 absorbance, so that the antigen-binding activity can be assessed. In place of a whole protein, its fragments, for example, fragments comprising its C-terminal or N-terminal, may be used. For the activity assay of the antibody of this invention, BIAcore (Pharmacia) can be used.

25 A method for detecting and measuring the protein of this invention can be carried out by using these techniques, the method comprising bringing the antibody of this invention into contact with a sample which is expected to contain the protein of this invention, and detecting or measuring an immune complex consisting of the  
30 antibody and the protein.

Since the method of this invention for detecting or measuring proteins is capable of selectively detecting or measuring proteins, it is useful for various experiments and such, using proteins.

The present invention includes polynucleotides hybridizing to  
35 a DNA comprising a base sequence set forth in SEQ ID NO: 1 or a DNA complementary to the DNA, and consisting of at least 15 bases. That

is, this invention includes probes, nucleotides or nucleotide derivatives, for example, antisense-oligonucleotides, ribozymes, and such, which are capable of selectively hybridizing to a DNA encoding the protein of this invention or a DNA complementary to the DNA.

This invention includes an antisense oligonucleotide, for example, hybridizing to any site of the base sequence set forth in SEQ ID NO: 1. This is preferably an antisense oligonucleotide to a nucleotide comprising at least 15 or more consecutive nucleotides in the base sequence set forth in SEQ ID NO: 1. More preferably, the antisense oligonucleotide comprises at least 15 or more consecutive bases containing the translation initiation codon.

Derivatives and modified products of antisense oligonucleotides can be used as the antisense oligonucleotide. Such modified products include those modified with low alkyl phosphonates, such as the methyl phosphonate type and ethyl phosphonate type, those modified with phosphorothionate or phosphoroamidate, etc.

Herein, "antisense oligonucleotide" includes not only nucleotides corresponding to those constituting a predetermined region of a DNA or mRNA of which are all complementary to the DNA or mRNA, but also nucleotides having one or a plurality of mismatched nucleotides so far as they can selectively as well as stably hybridize to the base sequence set forth in SEQ ID NO: 1.

Herein, the phrase "selectively and stably hybridize" means that a DNA does not significantly cross-hybridize to other DNAs encoding other proteins under usual hybridization conditions, preferably under a stringent hybridization conditions. Such a polynucleotide refers to the one which has a base sequence of at least 15 consecutive nucleotides, and has at least 70% or more, preferably at least 80% or more, more preferably at least 90% or more, and further more preferably at least 95% or more of base sequence identity to a nucleotide to be hybridized. Algorithms described in this specification can be used to determine the sequence homology. Such polynucleotides are useful, as described below in examples, as probes for detecting or isolating a DNA encoding the protein of this invention or as primer for amplifying the DNA.



Derivatives of antisense oligonucleotides of this invention have a suppressive effect on the action of the proteins of this invention resulting from the repression of the expression of the protein caused by their action on cells producing the protein of this invention and  
5 binding to DNA or mRNA encoding the protein to suppress the transcription or translation thereof or enhance the decomposition of mRNA.

Derivatives of antisense oligonucleotides of this invention can be mixed with appropriate bases inert to them to prepare the external  
10 preparation such as salve, cataplasm, etc.

In addition, as the occasion demands, excipients, isotonicity agents, solubilizers, stabilizers, antiseptics, soothing agents, and such, are added to the above-described derivatives to prepare tablets, powder agents, granules, capsules, liposome capsules,  
15 injection agents, liquid preparations, nasal drops, and such, and further lyophilized preparations. They can be prepared according to a standard method.

Derivatives of antisense oligonucleotides of this invention are either directly applied to the affected region of patient or  
20 intravascularly administered, for example, to patient, so that they can eventually reach the affected region. Furthermore, antisense nucleotide enclosing materials can be used to enhance the durability or membrane permeability, including liposome, poly-L-lysine, lipid, cholesterol, lipofectin, or derivatives thereof.

Doses of derivatives of antisense oligonucleotides of this invention can be appropriately adjusted according to the conditions of patients, and used in preferable amounts. For example, they can be administered in the range 0.1~100 mg/kg, preferably 0.1~50 mg/kg.  
25

The antisense oligonucleotides of this invention inhibit the expression of the protein of this invention and, thus, are useful  
30 for suppressing its biological activities. Expression inhibitors comprising antisense oligonucleotides of this invention are useful in that they can suppress biological activities of the protein of this invention.

35

#### Brief Description of the Drawings

Fig. 1 represents a photograph showing the results of Northern blot analysis of the hh00149 gene.

"H" in the figure represents the results of detection obtained using Human MTN Blot (CLONTECH, catalogue No. 7760-1), showing 1. heart, 2. brain, 3. placenta, 4. lung, 5. liver, 6. skeletal muscle, 7. kidney and 8. Pancreas. "H4" represents the results of detection obtained using Human MTN Blot IV (CLONTECH, catalogue No. 7766-1), showing 1. spleen, 2. thymus, 3. prostate, 4. testis, 5. uterus, 6. small intestine, 7. colon and 8. peripheral lymphocyte.

10 "F" represents the results of detection using Human Fetal MTN Blot II (CLONTECH, catalogue No. 7756-1), showing 1. fetal brain, 2. fetal lung, 3. fetal liver and 4. fetal kidney.

"C" represents the results of detection using Human Cancer Cell Line MTN Blot II (CLONTECH, catalogue No. 7757-1), showing 1. acute leukemia HL-60 cell, 2. HeLa cell S3, 3. chronic myelocytic leukemia K-562 cell, 4. lymphoblastic leukemia MOLT-4 cell, 5. Burkitt's lymphoma Raji cell, 6. colorectal adenocarcinoma SW-480 cell, 7. lung cancer A549 cell and 8. melanoma G361 cell, respectively.

"B2" represents the results of detection using Human Brain MTN Blot II (CLONTECH, catalogue No. 7755-1), showing 1. cerebellum, 2. cerebral cortex, 3. medulla oblongata, 4. spinal cord, 5. occipital lobe, 6. frontal lobe, 7. temporal lobe and 8. putamen, respectively.

"B4" represents the results of detection using Human Brain MTN Blot IV (CLONTECH, catalogue No. 7769-1), 1. cerebellar tonsil, 2. caudatum, 3. corpus callosum, 4. hippocampus, 5. whole brain, 6. nigra and 7. thalamus.

Fig. 2 represents photographs showing the results of RT-PCR. The first strand cDNAs used were 32 in total, derived from 1. brain, 2. heart, 3. kidney, 4. liver, 5. lung, 6. pancreas, 7. placenta, 8. skeletal muscle, 9. large intestine, 10. ovary, 11. peripheral lymphocyte, 12. prostate, 13. small intestine, 14. spleen, 15. testis, 16. thymus, 17. fetal brain, 18. fetal heart, 19. fetal kidney, 20. fetal liver, 21. fetal lung, 22. fetal skeletal muscle, 23. fetal spleen, 24. fetal thymus, 25. breast carcinoma (GI-101), 26. lung carcinoma (LX-1), 27. colon adenocarcinoma (CX-1), 28. lung carcinoma (GI-117), 29. prostatic adenocarcinoma (PC-3), 30. colon

adenocarcinoma (GI-112), 31. ovarian carcinoma (GI-102) and 32. pancreatic adenocarcinoma (GI-103) (CLONTECH, catalogue Nos. K1420-1, K1421-1, K1425-1, and K1422-1). Results of RT-PCR for detecting the hh-00149 gene and G3PDH gene (control) are indicated above and below, respectively.

Fig. 3 is a diagram showing an expected structure of the hh00149 protein. In this figure, the diamond-shaped mark represents a hydrophobic region, and oval-shaped mark a hydrophilic region, respectively.

#### Best Mode for Carrying out the Invention

The present invention is described below in more detail with reference to examples, but is not construed as being limited thereto. Example 1 - Construction of library of size-fractionated human brain cDNAs

cDNAs were constructed according to the method of Ohara (DNA Research 4, 53-59 (1997)). Specifically, double-stranded cDNAs were synthesized from Human poly A + RNA whole brain (CLONTECH, catalogue No. 6516-1) using the SuperScript II reverse transcriptase (GibcoBRL, catalogue No. 18064-014) with a (dT)15 primer having the Not I site at the 5' terminal end (GACTAGTTCT AGATCGCGAG CGGCCGCCCT TTTTTTTTTT TTTT/SEQ ID NO: 3) according to the manual. cDNAs thus obtained were digested with the restriction enzyme Not I, and then ligated to the Sal I adaptors. Sal I adaptors used are shown in Table 1.

Table 1

|                                  |                |
|----------------------------------|----------------|
| 5'-TCGACCCACGCGTCCG-3'           | (SEQ ID NO: 4) |
| 3'-GGGTGCGCAGGC <sub>p</sub> -5' | (SEQ ID NO: 5) |

cDNAs shorter than 3 kb were removed by electrophoresis on 1% low-melting point agarose gel, and cDNA fragments larger than 3 kb in size were ligated to the pBluescript II SK+ (STRATAGENE, catalogue No. 212205) which had been digested with Not I and Sal I, and then transferred into ElectroMax DH10B<sup>TM</sup> cells (GibcoBRL, catalogue No: 18290-015) by electroporation according to the manual. Plasmid DNAs

were extracted from the independent  $8 \times 10^6$  colonies obtained as the ampicillin-resistant colonies on agar plates by the standard alkali/SDS cytolysis method. A majority of plasmid DNAs thus obtained are the closed circular DNAs, so that their sizes  
 5 fractionated by electrophoresis reflect the sizes of inserted cDNAs. Therefore, plasmid DNAs which were separated into 10 fractions on 1% agarose gel correspond to fractions separated by the size of cDNAs. Each of these fractions was separately transferred again into *E. coli*, and plasmids were extracted from  $1 \times 10^6$  colonies or more per each  
 10 fraction. In this case, the transformed *E. coli* was cultured on shaking in LB medium containing 100  $\mu\text{g/ml}$  ampicillin for 3 hr. Plasmids thus extracted were confirmed of their sizes by electrophoresis, and the size selection was repeated at least twice for plasmids of 8 kb or less in size, and three times for the cDNA  
 15 inserts of 8 kb or more in size to construct libraries of cDNAs fractionated by size.

#### Example 2 - Cloning of hh00149 gene

Plasmid DNA was extracted from the above-described library of fractionated cDNAs, and sequenced. Plasmid DNA was extracted using  
 20 the PI-100 automatic plasmid DNA extraction apparatus (Kurabo). The dye-primer cycle sequencing reaction was automatically performed by the CATALYST Turbo (Perkin-Elmer) using the ABI PRISM™ cycle-sequencing kit (Perkin-Elmer). Reaction products were electrophoresed using either ABI373A or ABI377 DNA sequencer,  
 25 analyzed by the ABI sequence analysis system, INHERIT. cDNA inserts were sequenced from both terminals using the Dye-labeled M13 forward primer (Perkin-Elmer) and reverse primer (Perkin-Elmer). Furthermore, the entire base sequence of cDNA was determined using the shotgun method. The hh00149 gene was sequenced as one of the  
 30 clones. The base sequence and putative amino acid sequence of hh00149 are shown in SEQ ID NOs: 1 and 2, respectively.

#### Example 3 - Chromosome mapping

The locus of hh00149 gene was mapped on chromosomes using the Gene Bridge 4 Radiation Hybrid Panel (Research Genetics, Inc.). The  
 35 10x KOD dash buffer (2  $\mu\text{l}$ ), 2.5 mM dNTP (1.6  $\mu\text{l}$ ), 10  $\mu\text{M}$  primer 149-2867 (CAGGGTGGGA GAAGGGGAAA GAATC/SEQ ID NO: 6) (0.8  $\mu\text{l}$ ), 10  $\mu\text{M}$  primer

149-2944 (GAGGCCATTG ACAGGGAGAC GAAAC/SEQ ID NO: 7) (0.8  $\mu$ l), sterilized water (13.4  $\mu$ l) and KOD dash DNA polymerase (TOYOBO #LDP-101) (0.4  $\mu$ l) were mixed, warmed at 94°C for 5 min, and then subjected to the polymerase chain reaction (PCR) of 40 repeated  
 5 cycles of 98°C for 10 sec, 60°C for 2 sec and 74°C for 10 sec to amplify the gene. The results were analyzed using the analysis software downloaded from the World Wide Web (<http://www.sph.umich.edu/group/statgen/software>). As a result, the hh00149 gene was mapped 3.2 cR from the landmark WI-4142 on  
 10 chromosome 6.

#### Example 4 - Tissue specificity of hh00149 gene expression by Northern blot analysis

Northern blot analysis was performed according to the usual method, using the MTN Blot (CLONTECH, catalogue Nos.: 7760-1, 7766-1, 15 7756-1, 7757-1, 7755-1 and 7769-1) with an Nco I fragment (corresponding to bases 948 to 1574 in SEQ ID NO: 1) (25 ng) which had been labeled with [ $\alpha$ -<sup>32</sup>P]dCTP using the Megaprime DNA labelling kit (Amersham, catalogue No. RPN1607) to serve as a probe. Prehybridization was carried out in the ExpressHyb Hybridization  
 20 Solution (CLONTECH, catalogue No. 8015-2) (20 ml) at 68°C for 30 min, and then hybridization was performed with the above-described labeled probe ( $2 \times 10^7$  cpm) similarly in the ExpressHyb Hybridization Solution (20 ml) ( $1 \times 10^6$  cpm/ml) at 68°C for 1 hr. The filter was washed three times at room temperature for 10 min each using 2x SSC  
 25 (0.3 M NaCl and 0.03 M sodium citrate (pH 7.0))/0.05% SDS) followed by further washing twice in 0.1x SSC/0.1% SDS at 50°C for 15 min. Then a FUJI Imaging plate (Fuji film) was exposed to the filter overnight, and analyzed using the FUJI BAS2000 (Fuji Film). As a result, a transcription product of 3.2 kb was specifically detected  
 30 in the brain, and found to be strongly expressed, as the result of analysis using the Human Brain MTN Blot II (catalogue No.: 7755-1) and Human Brain MTN Blot IV (catalogue No.: 7769-1), in the cerebral cortex, occipital lobe, frontal lobe and temporal lobe, and also to be expressed in the cerebellum, putamen and cerebellar tonsil.  
 35 Besides the brain, its expression was confirmed also in the spleen, testis and lung cancer A549 cells (Fig. 1).

Example 5 - RT-PCR analysis of tissue specificity of hh00149 gene expression

The expression amount of mRNA in 32 different tissues including those which had been analyzed by Northern blot was compared by RT-PCR to analyze the tissue specificity of the hh00149 gene expression. cDNAs used were the Human MTC Panel I (K1402-1), Human MTC Panel II (K1421-1), Human Fetal MTC Panel I (K1425-1) and Human Tumor MTC Panel I (K1422-1) commercially available from CLONTECH. The 10x KOD dash buffer (2  $\mu$ l), 2.5 mM dNTP (1.6  $\mu$ l), 10  $\mu$ M primer 149-2867 (CAGGGTGGGA GAAGGGGAAA GAATC/SEQ ID NO: 6) (0.8  $\mu$ l), 10  $\mu$ M primer 149-2944 (GAGGCCATTG ACAGGGAGAC GAAAC/SEQ ID NO: 7) (0.8  $\mu$ l), sterilized water (13.4  $\mu$ l) and KOD dash DNA polymerase (TOYOBO #LDP-101) (0.4  $\mu$ l) were mixed, warmed at 94°C for 5 min, and then subjected to the polymerase chain reaction (PCR) of 30 repeated cycles of 98°C for 10 sec, 60°C for 2 sec and 74°C for 10 sec. The results are shown in Fig. 2. Considerable high level of the gene expression was detected in the adult and fetal brains. The gene expression was also detected in the testis, spleen and ovary, but in no other tissues.

Example 6 - Prediction of hh00149 protein structure

The structure of the hh00149 protein was predicted using "peptide structure" and "pepplot" of the GCG Sequence Analysis Software Package (Genetic Computer Group, Oxford Molecular Group, Inc.) (Fig. 3). As a result, the amino acid sequence at the amino terminal (amino acids 1 to 20) and that (amino acids 527 to 557) are abundant in hydrophobicity, the former of which is thought to function as the signal sequence, and the latter as the transmembrane region.

Industrial Applicability

Since the membrane protein of this invention is indicated to function as a signal transducer molecule from outside to inside the cell in the brain, the membrane protein and the gene thereof are expected to be used for screening novel signal transducing substances, including neuropeptides. The membrane protein of this invention and gene thereof are expected to be applied in the development of novel remedies and diagnostics for nerve-related disorders.

## CLAIMS

1. A DNA selected from the group consisting of the following (a) through (e):

5 (a) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2;

(b) a DNA comprising the coding region of the base sequence set forth in SEQ ID NO: 1;

10 (c) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2 which is modified by deletion and/or addition of one or more amino acid residues, and/or substitution with other amino acids, and functionally equivalent to the protein comprising the amino acid sequence set forth in SEQ ID NO: 2;

15 (d) a DNA hybridizing to the DNA comprising the base sequence set forth in SEQ ID NO: 1, and encoding a protein functionally equivalent to the protein comprising the amino acid sequence set forth in SEQ ID NO: 2; and

(e) a DNA comprising a DNA according to any of (a) through (d) and a DNA encoding other peptide or polypeptide, encoding a fusion protein.

20 2. A vector having the DNA according to claim 1 inserted therein.

3. A transformant carrying the DNA according to claim 1 or the vector according to claim 2.

4. A protein encoded by the DNA according to claim 1.

5. A method for producing the protein according to claim 4, said  
25 method comprising the steps of culturing the transformant according to claim 3 and recovering the expressed protein from said transformant or the culture supernatant thereof.

6. An antibody binding to the protein according to claim 4.

7. A method of screening for a compound which binds to the protein  
30 according to claim 4, said method comprising the steps of:

(a) bringing the protein according to claim 4 into contact with a sample to be tested, and

(b) selecting a compound having the activity to bind to the protein according to claim 4.

35 8. A method for detecting or measuring the protein according to claim 4, said method comprising bringing the antibody according to

claim 6 into contact with a test sample that apparently contains the protein according to claim 4, and detecting or measuring the formation of an immune complex of said antibody and said protein.

9. A polynucleotide hybridizing to the DNA comprising the base  
5 sequence according to SEQ ID NO: 1 or a complementary strand thereof  
and having a chain length of at least 15 bases.





|   |      |
|---|------|
| cgg aca gtg gag ctg cgc ctg ggc ggc aac ttc atc atc cac atc agc<br>Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile Ile His Ile Ser<br>55 60 65        | 669  |
| cgc cag gac ttt gcc aac atg acg ggg ctg gtg gac ctg acc ctg tcc<br>Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp Leu Thr Leu Ser<br>70 75 80        | 717  |
| agg aac acc atc agc cac atc cag ccc ttt tcc ttt ctg gac ctc gag<br>Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe Leu Asp Leu Glu<br>85 90 95 100    | 765  |
| agc ctc cgc tcc ctg cat ctt gac agc aat cgg ctg cca agc ctt ggg<br>Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu Pro Ser Leu Gly<br>105 110 115     | 813  |
| gag gac acc ctc cgg ggc ctg gtc aac ctg cag cac ctt atc gtg aac<br>Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His Leu Ile Val Asn<br>120 125 130     | 861  |
| aac aac cag ctg ggc ggc atc gca gat gag gct ttt gag gac ttc ctg<br>Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe Glu Asp Phe Leu<br>135 140 145     | 909  |
| ctg aca ttg gag gat ctg gac ctc tcc tac aac aac ctc cat ggc ctg<br>Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu His Gly Leu<br>150 155 160     | 957  |
| ccg tgg gac tcc gtg cga cgc atg gtc aac ctc cac cag ctg agc ctg<br>Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His Gln Leu Ser Leu<br>165 170 175 180 | 1005 |
| gac cac aac ctg ctg gat cac atc gcc gag ggc acc ttt gca gac ctg<br>Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr Phe Ala Asp Leu<br>185 190 195     | 1053 |
| cag aaa ctg gcc cgc ctg gat ctc acc tcc aat cgg ctg cag aag ctg<br>Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg Leu Gln Lys Leu<br>200 205 210     | 1101 |
| ccc cct gat ccc atc ttt gcc cgc tcc cag gct tcg gct ttg aca gcc<br>Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser Ala Leu Thr Ala<br>215 220 225     | 1149 |
| aca ccc ttt gcc cca ccc ttg tcc ttt agt ttt ggg ggt aac cca ctt<br>Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly Gly Asn Pro Leu<br>230 235 240     | 1197 |
| cac tgc aat tgt gag ctt ctc tgg ctg cgg agg ctc gag cgg gac gat<br>His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Glu Arg Asp Asp<br>245 250 255 260 | 1245 |
| gac ctg gaa acc tgt ggc tcc cca ggg ggc ctc aag ggt cgc tac ttc<br>Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys Gly Arg Tyr Phe<br>265 270 275     | 1293 |
| tgg cat gtg cgt gag gag gag ttt gtg tgc gag ccg cct ctc atc acc   | 1341 |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|--|
| Trp | His | Val | Arg | Glu | Glu | Glu | Phe | Val | Cys | Glu | Pro | Pro | Leu | Ile | Thr |      |  |
|     |     |     | 280 |     |     |     |     | 285 |     |     |     |     | 290 |     |     |      |  |
| cag | cac | aca | cac | aag | ttg | ctg | gtt | ctg | gag | ggc | cag | gcg | gcc | aca | ctc | 1389 |  |
| Gln | His | Thr | His | Lys | Leu | Leu | Val | Leu | Glu | Gly | Gln | Ala | Ala | Thr | Leu |      |  |
|     |     | 295 |     |     |     |     | 300 |     |     |     |     | 305 |     |     |     |      |  |
| aag | tgc | aaa | gcc | att | ggg | gac | ccc | agc | ccc | ctt | atc | cac | tgg | gta | gcc | 1437 |  |
| Lys | Cys | Lys | Ala | Ile | Gly | Asp | Pro | Ser | Pro | Leu | Ile | His | Trp | Val | Ala |      |  |
|     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |     |     |     |     |      |  |
| ccc | gat | gac | cgc | ctg | gta | ggg | aac | tcc | tca | agg | acc | gct | gtc | tat | gac | 1485 |  |
| Pro | Asp | Asp | Arg | Leu | Val | Gly | Asn | Ser | Ser | Arg | Thr | Ala | Val | Tyr | Asp |      |  |
| 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |     |     |     | 340 |      |  |
| aat | ggc | acc | ctg | gac | atc | ttc | atc | acc | aca | tct | cag | gac | agt | ggg | gcc | 1533 |  |
| Asn | Gly | Thr | Leu | Asp | Ile | Phe | Ile | Thr | Thr | Ser | Gln | Asp | Ser | Gly | Ala |      |  |
|     |     |     | 345 |     |     |     |     | 350 |     |     |     |     |     | 355 |     |      |  |
| ttc | acc | tgc | att | gct | gcc | aat | gct | gcc | gga | gag | gcc | acg | gcc | atg | gtg | 1581 |  |
| Phe | Thr | Cys | Ile | Ala | Ala | Asn | Ala | Ala | Gly | Glu | Ala | Thr | Ala | Met | Val |      |  |
|     |     |     | 360 |     |     |     | 365 |     |     |     |     |     | 370 |     |     |      |  |
| gag | gtc | tcc | atc | gtc | cag | ctg | cca | cac | ctc | agc | aac | agc | acc | agc | cgc | 1629 |  |
| Glu | Val | Ser | Ile | Val | Gln | Leu | Pro | His | Leu | Ser | Asn | Ser | Thr | Ser | Arg |      |  |
|     |     | 375 |     |     |     |     | 380 |     |     |     |     | 385 |     |     |     |      |  |
| act | gca | ccc | ccc | aag | tcc | cgc | ctc | tca | gac | atc | act | ggc | tcc | agc | aag | 1677 |  |
| Thr | Ala | Pro | Pro | Lys | Ser | Arg | Leu | Ser | Asp | Ile | Thr | Gly | Ser | Ser | Lys |      |  |
|     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |     |     |     |     |      |  |
| acc | agc | cgg | gga | ggg | gga | ggc | agt | ggg | ggc | gga | gag | cct | ccc | aaa | agc | 1725 |  |
| Thr | Ser | Arg | Gly | Gly | Gly | Gly | Ser | Gly | Gly | Gly | Glu | Pro | Pro | Lys | Ser |      |  |
| 405 |     |     |     | 410 |     |     |     |     | 415 |     |     |     |     |     | 420 |      |  |
| ccc | ccg | gaa | cgg | gct | gtg | ctt | gtg | tct | gaa | gtg | acc | acc | acc | tgc | gcc | 1773 |  |
| Pro | Pro | Glu | Arg | Ala | Val | Leu | Val | Ser | Glu | Val | Thr | Thr | Thr | Ser | Ala |      |  |
|     |     |     | 425 |     |     |     |     | 430 |     |     |     |     |     | 435 |     |      |  |
| ctg | gtc | aag | tgg | tct | gtc | agc | aag | tca | gca | ccc | cgg | gtg | aag | atg | tac | 1821 |  |
| Leu | Val | Lys | Trp | Ser | Val | Ser | Lys | Ser | Ala | Pro | Arg | Val | Lys | Met | Tyr |      |  |
|     |     | 440 |     |     |     |     | 445 |     |     |     |     |     | 450 |     |     |      |  |
| cag | ctg | cag | tac | aac | tgc | tct | gac | gat | gag | gta | ctg | att | tac | agg | atg | 1869 |  |
| Gln | Leu | Gln | Tyr | Asn | Cys | Ser | Asp | Asp | Glu | Val | Leu | Ile | Tyr | Arg | Met |      |  |
|     |     | 455 |     |     |     |     | 460 |     |     |     |     | 465 |     |     |     |      |  |
| atc | cca | gcc | tcc | aac | aag | gcc | ttc | gtg | gtc | aac | aac | ctg | gtg | tca | ggg | 1917 |  |
| Ile | Pro | Ala | Ser | Asn | Lys | Ala | Phe | Val | Val | Asn | Asn | Leu | Val | Ser | Gly |      |  |
|     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |     |     |     |     |      |  |
| act | ggc | tac | gac | ttg | tgt | gtg | ctg | gcc | atg | tgg | gat | gac | aca | gcc | acg | 1965 |  |
| Thr | Gly | Tyr | Asp | Leu | Cys | Val | Leu | Ala | Met | Trp | Asp | Asp | Thr | Ala | Thr |      |  |
| 485 |     |     |     | 490 |     |     |     |     |     | 495 |     |     |     |     | 500 |      |  |
| aca | ctc | acg | gcc | acc | aac | atc | gtg | ggc | tgc | gcc | cag | ttc | ttc | acc | aag | 2013 |  |
| Thr | Leu | Thr | Ala | Thr | Asn | Ile | Val | Gly | Cys | Ala | Gln | Phe | Phe | Thr | Lys |      |  |

| 505 |     |     |     |     |     |     |     |     |     | 510 |     |     |     |     | 515 |  |      |  |  |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|------|--|--|--|
| gct | gac | tac | ccg | cag | tgc | cag | tcc | atg | cac | agc | cag | att | ctg | ggc | ggc |  | 2061 |  |  |  |
| Ala | Asp | Tyr | Pro | Gln | Cys | Gln | Ser | Met | His | Ser | Gln | Ile | Leu | Gly | Gly |  |      |  |  |  |
|     |     |     | 520 |     |     |     |     | 525 |     |     |     |     | 530 |     |     |  |      |  |  |  |
| acc | atg | atc | ctg | gtc | atc | ggg | ggc | atc | atc | gtg | gcc | acg | ctg | ctg | gtc |  | 2109 |  |  |  |
| Thr | Met | Ile | Leu | Val | Ile | Gly | Gly | Ile | Ile | Val | Ala | Thr | Leu | Leu | Val |  |      |  |  |  |
|     |     | 535 |     |     |     | 540 |     |     |     |     | 545 |     |     |     |     |  |      |  |  |  |
| ttc | atc | gtc | atc | ctc | atg | gtg | cgc | tac | aag | gtc | tgc | aac | cac | gag | gcc |  | 2157 |  |  |  |
| Phe | Ile | Val | Ile | Leu | Met | Val | Arg | Tyr | Lys | Val | Cys | Asn | His | Glu | Ala |  |      |  |  |  |
|     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |     |     |     |     |  |      |  |  |  |
| ccc | agc | aag | atg | gca | gcg | gcc | gtg | agc | aat | gtg | tac | tcg | cag | acc | aac |  | 2205 |  |  |  |
| Pro | Ser | Lys | Met | Ala | Ala | Ala | Val | Ser | Asn | Val | Tyr | Ser | Gln | Thr | Asn |  |      |  |  |  |
| 565 |     |     |     |     | 570 |     |     |     | 575 |     |     |     |     |     | 580 |  |      |  |  |  |
| ggc | gcc | cag | cca | ccg | cct | cca | agc | agc | gca | cca | gcc | ggg | gcc | ccg | ccg |  | 2253 |  |  |  |
| Gly | Ala | Gln | Pro | Pro | Pro | Pro | Ser | Ser | Ala | Pro | Ala | Gly | Ala | Pro | Pro |  |      |  |  |  |
|     |     |     | 585 |     |     |     |     |     | 590 |     |     |     |     | 595 |     |  |      |  |  |  |
| cag | ggc | ccg | ccg | aag | gtg | gtg | gtg | cgc | aac | gag | ctc | ctg | gac | ttc | acc |  | 2301 |  |  |  |
| Gln | Gly | Pro | Pro | Lys | Val | Val | Val | Arg | Asn | Glu | Leu | Leu | Asp | Phe | Thr |  |      |  |  |  |
|     |     |     | 600 |     |     |     |     | 605 |     |     |     |     | 610 |     |     |  |      |  |  |  |
| gcc | agc | ctg | gcc | cgc | gcc | agt | gac | tcc | tct | tcc | tcc | agc | tcc | ctg | ggc |  | 2349 |  |  |  |
| Ala | Ser | Leu | Ala | Arg | Ala | Ser | Asp | Ser | Ser | Ser | Ser | Ser | Ser | Leu | Gly |  |      |  |  |  |
|     |     | 615 |     |     |     |     | 620 |     |     |     |     | 625 |     |     |     |  |      |  |  |  |
| agt | ggg | gag | gct | gcg | ggg | ctg | gga | cgg | gcc | ccc | tgg | agg | atc | cca | ccc |  | 2397 |  |  |  |
| Ser | Gly | Glu | Ala | Ala | Gly | Leu | Gly | Arg | Ala | Pro | Trp | Arg | Ile | Pro | Pro |  |      |  |  |  |
|     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |     |     |     |     |  |      |  |  |  |
| tcc | gcc | ccg | cgc | ccc | aag | ccc | agc | ctt | gac | cgc | ctg | atg | ggg | gcc | ttc |  | 2445 |  |  |  |
| Ser | Ala | Pro | Arg | Pro | Lys | Pro | Ser | Leu | Asp | Arg | Leu | Met | Gly | Ala | Phe |  |      |  |  |  |
| 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |     |     |     | 660 |  |      |  |  |  |
| gcc | tcc | ctg | gac | ctc | aag | agt | cag | aga | aag | gag | gag | ctg | ctg | gac | tcc |  | 2493 |  |  |  |
| Ala | Ser | Leu | Asp | Leu | Lys | Ser | Gln | Arg | Lys | Glu | Glu | Leu | Leu | Asp | Ser |  |      |  |  |  |
|     |     |     | 665 |     |     |     |     | 670 |     |     |     |     |     | 675 |     |  |      |  |  |  |
| agg | act | cca | gcc | ggg | aga | ggg | gct | ggg | acg | tcg | gcc | cgg | ggc | cac | cac |  | 2541 |  |  |  |
| Arg | Thr | Pro | Ala | Gly | Arg | Gly | Ala | Gly | Thr | Ser | Ala | Arg | Gly | His | His |  |      |  |  |  |
|     |     | 680 |     |     |     |     | 685 |     |     |     |     |     | 690 |     |     |  |      |  |  |  |
| tcg | gac | cga | gag | cca | ctg | ctg | ggg | ccc | cct | gcg | gcc | cgg | gcc | agg | agc |  | 2589 |  |  |  |
| Ser | Asp | Arg | Glu | Pro | Leu | Leu | Gly | Pro | Pro | Ala | Ala | Arg | Ala | Arg | Ser |  |      |  |  |  |
|     |     | 695 |     |     |     |     | 700 |     |     |     |     | 705 |     |     |     |  |      |  |  |  |
| ctg | ctc | ccc | ttg | ccg | ttg | gag | ggc | aag | gcc | aaa | cgc | agc | cac | tcc | ttc |  | 2637 |  |  |  |
| Leu | Leu | Pro | Leu | Pro | Leu | Glu | Gly | Lys | Ala | Lys | Arg | Ser | His | Ser | Phe |  |      |  |  |  |
|     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |     |     |     |     |  |      |  |  |  |
| gac | atg | ggg | gac | ttt | gct | gct | gcg | gcg | gcg | gga | ggg | gtc | gtg | ccg | ggc |  | 2685 |  |  |  |
| Asp | Met | Gly | Asp | Phe | Ala | Ala | Ala | Ala | Ala | Gly | Gly | Val | Val | Pro | Gly |  |      |  |  |  |
| 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |     |     |     | 740 |  |      |  |  |  |

ggc tac agt cct cct cgg aag gtc tgc aac atc tgg acg aag cgc agc 2733  
 Gly Tyr Ser Pro Pro Arg Lys Val Ser Asn Ile Trp Thr Lys Arg Ser  
                     745                    750                    755

ctc tct gtc aac ggc atg ctc ttg ccc ttt gag gag agt gac ctg gtg 2781  
 Leu Ser Val Asn Gly Met Leu Leu Pro Phe Glu Glu Ser Asp Leu Val  
                     760                    765                    770

ggg gcc cgg ggg act ttt ggc agc tcc gaa tgg gtg atg gag agc acg 2829  
 Gly Ala Arg Gly Thr Phe Gly Ser Ser Glu Trp Val Met Glu Ser Thr  
                     775                    780                    785

gtc taggtggggg tgggcatgct ccctttcctg tgcgcagggt gggagaaggg 2882  
 Val

gaaagaatct cactggcaag tgtttgtgga gtttccatgg tgatgtttac atccagggac 2942  
 agtttctgtct cctgtcaat ggctctgtgt cccccctac cccgcaacac ccacatcacc 3002  
 tccccaccac ccggccgggg tgtgctcagg gaatgtggac tcgctcaaat gccggactga 3062  
 gccctgagtgt tttggaaagg cgagactccg cctttctaata cacaaatgta gcctacaagc 3122  
 aagcggcttt ggattgctta tg 3144

<210> 2

<211> 789

<212> PRT

<213> Homo sapiens

<400> 2

Met Glu Thr Leu Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala  
 1                    5                    10                    15  
 Val Val Asp Ala Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu  
                     20                    25                    30  
 Ser Leu Gly Thr Leu Cys Pro Ser Lys Gly Leu Leu Phe Val Pro Pro  
                     35                    40                    45  
 Asp Ile Asp Arg Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile  
                     50                    55                    60  
 Ile His Ile Ser Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp  
 65                    70                    75                    80  
 Leu Thr Leu Ser Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe  
                     85                    90                    95  
 Leu Asp Leu Glu Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu  
                     100                    105                    110  
 Pro Ser Leu Gly Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His  
                     115                    120                    125  
 Leu Ile Val Asn Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe  
 130                    135                    140  
 Glu Asp Phe Leu Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn  
 145                    150                    155                    160  
 Leu His Gly Leu Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His  
                     165                    170                    175  
 Gln Leu Ser Leu Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr  
                     180                    185                    190  
 Phe Ala Asp Leu Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg  
                     195                    200                    205  
 Leu Gln Lys Leu Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser  
                     210                    215                    220

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Leu | Thr | Ala | Thr | Pro | Phe | Ala | Pro | Pro | Leu | Ser | Phe | Ser | Phe | Gly |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| Gly | Asn | Pro | Leu | His | Cys | Asn | Cys | Glu | Leu | Leu | Trp | Leu | Arg | Arg | Leu |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     |     | 255 |
| Glu | Arg | Asp | Asp | Asp | Leu | Glu | Thr | Cys | Gly | Ser | Pro | Gly | Gly | Leu | Lys |
|     |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     |     | 270 |
| Gly | Arg | Tyr | Phe | Trp | His | Val | Arg | Glu | Glu | Glu | Phe | Val | Cys | Glu | Pro |
|     |     |     |     | 275 |     |     |     |     | 280 |     |     |     |     |     | 285 |
| Pro | Leu | Ile | Thr | Gln | His | Thr | His | Lys | Leu | Leu | Val | Leu | Glu | Gly | Gln |
|     |     |     |     | 290 |     |     |     |     | 295 |     |     |     |     |     | 300 |
| Ala | Ala | Thr | Leu | Lys | Cys | Lys | Ala | Ile | Gly | Asp | Pro | Ser | Pro | Leu | Ile |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |
| His | Trp | Val | Ala | Pro | Asp | Asp | Arg | Leu | Val | Gly | Asn | Ser | Ser | Arg | Thr |
|     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     |     | 335 |
| Ala | Val | Tyr | Asp | Asn | Gly | Thr | Leu | Asp | Ile | Phe | Ile | Thr | Thr | Ser | Gln |
|     |     |     |     | 340 |     |     |     |     | 345 |     |     |     |     |     | 350 |
| Asp | Ser | Gly | Ala | Phe | Thr | Cys | Ile | Ala | Ala | Asn | Ala | Ala | Gly | Glu | Ala |
|     |     |     |     | 355 |     |     |     |     | 360 |     |     |     |     |     | 365 |
| Thr | Ala | Met | Val | Glu | Val | Ser | Ile | Val | Gln | Leu | Pro | His | Leu | Ser | Asn |
|     |     |     |     | 370 |     |     |     |     | 375 |     |     |     |     |     | 380 |
| Ser | Thr | Ser | Arg | Thr | Ala | Pro | Pro | Lys | Ser | Arg | Leu | Ser | Asp | Ile | Thr |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Gly | Ser | Ser | Lys | Thr | Ser | Arg | Gly | Gly | Gly | Gly | Ser | Gly | Gly | Gly | Glu |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     |     | 415 |
| Pro | Pro | Lys | Ser | Pro | Pro | Glu | Arg | Ala | Val | Leu | Val | Ser | Glu | Val | Thr |
|     |     |     |     | 420 |     |     |     |     | 425 |     |     |     |     |     | 430 |
| Thr | Thr | Ser | Ala | Leu | Val | Lys | Trp | Ser | Val | Ser | Lys | Ser | Ala | Pro | Arg |
|     |     |     |     | 435 |     |     |     |     | 440 |     |     |     |     |     | 445 |
| Val | Lys | Met | Tyr | Gln | Leu | Gln | Tyr | Asn | Cys | Ser | Asp | Asp | Glu | Val | Leu |
|     |     |     |     | 450 |     |     |     |     | 455 |     |     |     |     |     | 460 |
| Ile | Tyr | Arg | Met | Ile | Pro | Ala | Ser | Asn | Lys | Ala | Phe | Val | Val | Asn | Asn |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Leu | Val | Ser | Gly | Thr | Gly | Tyr | Asp | Leu | Cys | Val | Leu | Ala | Met | Trp | Asp |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     |     | 495 |
| Asp | Thr | Ala | Thr | Thr | Leu | Thr | Ala | Thr | Asn | Ile | Val | Gly | Cys | Ala | Gln |
|     |     |     |     | 500 |     |     |     |     | 505 |     |     |     |     |     | 510 |
| Phe | Phe | Thr | Lys | Ala | Asp | Tyr | Pro | Gln | Cys | Gln | Ser | Met | His | Ser | Gln |
|     |     |     |     | 515 |     |     |     |     | 520 |     |     |     |     |     | 525 |
| Ile | Leu | Gly | Gly | Thr | Met | Ile | Leu | Val | Ile | Gly | Gly | Ile | Ile | Val | Ala |
|     |     |     |     | 530 |     |     |     |     | 535 |     |     |     |     |     | 540 |
| Thr | Leu | Leu | Val | Phe | Ile | Val | Ile | Leu | Met | Val | Arg | Tyr | Lys | Val | Cys |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Asn | His | Glu | Ala | Pro | Ser | Lys | Met | Ala | Ala | Ala | Val | Ser | Asn | Val | Tyr |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     |     | 575 |
| Ser | Gln | Thr | Asn | Gly | Ala | Gln | Pro | Pro | Pro | Pro | Ser | Ser | Ala | Pro | Ala |
|     |     |     |     | 580 |     |     |     |     | 585 |     |     |     |     |     | 590 |
| Gly | Ala | Pro | Pro | Gln | Gly | Pro | Pro | Lys | Val | Val | Val | Arg | Asn | Glu | Leu |
|     |     |     |     | 595 |     |     |     |     | 600 |     |     |     |     |     | 605 |
| Leu | Asp | Phe | Thr | Ala | Ser | Leu | Ala | Arg | Ala | Ser | Asp | Ser | Ser | Ser | Ser |
|     |     |     |     | 610 |     |     |     |     | 615 |     |     |     |     |     | 620 |
| Ser | Ser | Leu | Gly | Ser | Gly | Glu | Ala | Ala | Gly | Leu | Gly | Arg | Ala | Pro | Trp |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Arg | Ile | Pro | Pro | Ser | Ala | Pro | Arg | Pro | Lys | Pro | Ser | Leu | Asp | Arg | Leu |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     |     | 655 |
| Met | Gly | Ala | Phe | Ala | Ser | Leu | Asp | Leu | Lys | Ser | Gln | Arg | Lys | Glu | Glu |
|     |     |     |     | 660 |     |     |     |     | 665 |     |     |     |     |     | 670 |
| Leu | Leu | Asp | Ser | Arg | Thr | Pro | Ala | Gly | Arg | Gly | Ala | Gly | Thr | Ser | Ala |

|                             |                         |                 |
|-----------------------------|-------------------------|-----------------|
| 675                         | 680                     | 685             |
| Arg Gly His His Ser Asp     | Arg Glu Pro Leu Leu Gly | Pro Pro Ala Ala |
| 690                         | 695                     | 700             |
| Arg Ala Arg Ser Leu Leu Pro | Leu Pro Leu Glu Gly Lys | Ala Lys Arg     |
| 705                         | 710                     | 715             |
| Ser His Ser Phe Asp Met Gly | Asp Phe Ala Ala Ala     | Ala Ala Gly Gly |
| 725                         | 730                     | 735             |
| Val Val Pro Gly Gly Tyr Ser | Pro Pro Arg Lys Val Ser | Asn Ile Trp     |
| 740                         | 745                     | 750             |
| Thr Lys Arg Ser Leu Ser Val | Asn Gly Met Leu Leu Pro | Phe Glu Glu     |
| 755                         | 760                     | 765             |
| Ser Asp Leu Val Gly Ala Arg | Gly Thr Phe Gly Ser Ser | Glu Trp Val     |
| 770                         | 775                     | 780             |
| Met Glu Ser Thr Val         |                         |                 |
| 785                         |                         |                 |

<210> 3  
 <211> 44  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: an  
 artificially synthesized primer sequence.

<400> 3  
 gactagttct agatcgcgag cggccgccct tttttttttt tttt

44

<210> 4  
 <211> 16  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: an  
 artificially synthesized adapter sequence.

<400> 4  
 tcgacccacg cgtccg

16

<210> 5  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: an  
 artificially synthesized adapter sequence.

<400> 5  
 cggacgcgtg gg

12

<210> 6  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<223> Description of Artificial Sequence: an artificially synthesized primer sequence.

25

<213> Artificial Sequence

<223> Description of Artificial Sequence: an artificially synthesized primer sequence.

25



Figure 1




Figure 2





Figure 3



## SEQUENCE LISTING

<110> CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.

Kazusa DNA Research Institute

<120> Novel gene encoding brain-specific membrane protein

<130> C2-010PCT

<150> JP 1998-331727

<151> 1998-11-20

<160> 7

<210> 1

<211> 3144

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (466).. (2832)

&lt;400&gt; 1

gcctggctcc ctctcgctga gacacacata cactcacaca tacacaaccc ggcaggctcg 60

tctgaacttg aagacacccc acattccaag atgcccaggg ttcttgggaa tgcctggggt 120

tcttcgatcc ggaaaatcct accggcatcc tcttagggag ggattattat tattatTTTT 180

ctttaatctg gaagagaaga gaacaagttg tgcttttccc cctttcttct tgctaaacgc 240

catggatata actgaataag cggtcaggg ctttccccgc gtggacgtcc gaggccacca 300

tctgcctgca ttgcgcggag ccgcccaggg gtttagctcg agtctgtctc gggcggggaa 360

ggatgcgtgg ccgagccggg gagcccgggc gcccgcgga gccggcctcg gtgccacca 420

gccgggggta gatctgcct cgcccaggcg ctgagtgacc agaoc atg gag acc ctg 477

Met Glu Thr Leu

1

ctt ggt ggc ctg cta gcg ttt ggc atg gcg ttt gcc gtg gtc gac gcc 525

Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala Val Val Asp Ala

5

10

15

20

tgc ccc aag tac tgt gtc tgc cag aat ctg tct gag tca ctg ggg acc 573

Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu Ser Leu Gly Thr

25

30

35

ctg tgc ccc tcc aag ggg ctg ctc ttt gta ccc cct gat att gac cgg 621

Leu Cys Pro Ser Lys Gly Leu Leu Phe Val Pro Pro Asp Ile Asp Arg

40

45

50

cgg aca gtg gag ctg cgc ctg ggc ggc aac ttc atc atc cac atc agc 669

Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile Ile His Ile Ser

55

60

65

cgc cag gac ttt gcc aac atg acg ggg ctg gtg gac ctg acc ctg tcc 717

Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp Leu Thr Leu Ser

70

75

80

agg aac acc atc agc cac atc cag ccc ttt tcc ttt ctg gac ctc gag 765

Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe Leu Asp Leu Glu

85

90

95

100

agc ctc cgc tcc ctg cat ctt gac agc aat cgg ctg cca agc ctt ggg 813

Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu Pro Ser Leu Gly

105

110

115

gag gac acc ctc cgg ggc ctg gtc aac ctg cag cac ctt atc gtg aac 861

Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His Leu Ile Val Asn

120

125

130

aac aac cag ctg ggc ggc atc gca gat gag gct ttt gag gac ttc ctg 909

Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe Glu Asp Phe Leu

135

140

145

ctg aca ttg gag gat ctg gac ctc tcc tac aac aac ctc cat ggc ctg 957

Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu His Gly Leu

150

155

160

ccg tgg gac tcc gtg cga cgc atg gtc aac ctc cac cag ctg agc ctg 1005

Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His Gln Leu Ser Leu

165

170

175

180

gac cac aac ctg ctg gat cac atc gcc gag ggc acc ttt gca gac ctg 1053

Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr Phe Ala Asp Leu

185

190

195

cag aaa ctg gcc cgc ctg gat ctc acc tcc aat cgg ctg cag aag ctg 1101

Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg Leu Gln Lys Leu

200

205

210

ccc cct gat ccc atc ttt gcc cgc tcc cag gct tcg gct ttg aca gcc 1149

Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser Ala Leu Thr Ala

215

220

225

aca ccc ttt gcc cca ccc ttg tcc ttt agt ttt ggg ggt aac cca ctt 1197

Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly Gly Asn Pro Leu

230

235

240

cac tgc aat tgt gag ctt ctc tgg ctg cgg agg ctc gag cgg gac gat 1245  
 His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Glu Arg Asp Asp  
 245 250 255 260

gac ctg gaa acc tgt ggc tcc cca ggg ggc ctc aag ggt cgc tac ttc 1293  
 Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys Gly Arg Tyr Phe  
 265 270 275

tgg cat gtg cgt gag gag gag ttt gtg tgc gag ccg cct ctc atc acc 1341  
 Trp His Val Arg Glu Glu Glu Phe Val Cys Glu Pro Pro Leu Ile Thr  
 280 285 290

cag cac aca cac aag ttg ctg gtt ctg gag ggc cag gcg gcc aca ctc 1389  
 Gln His Thr His Lys Leu Leu Val Leu Glu Gly Gln Ala Ala Thr Leu  
 295 300 305

aag tgc aaa gcc att ggg gac ccc agc ccc ctt atc cac tgg gta gcc 1437  
 Lys Cys Lys Ala Ile Gly Asp Pro Ser Pro Leu Ile His Trp Val Ala  
 310 315 320

ccc gat gac cgc ctg gta ggg aac tcc tca agg acc gct gtc tat gac 1485  
 Pro Asp Asp Arg Leu Val Gly Asn Ser Ser Arg Thr Ala Val Tyr Asp  
 325 330 335 340

aat ggc acc ctg gac atc ttc atc acc aca tct cag gac agt ggt gcc 1533



Asn Gly Thr Leu Asp Ile Phe Ile Thr Thr Ser Gln Asp Ser Gly Ala

345

350

355

ttc acc tgc att gct gcc aat gct gcc gga gag gcc acg gcc atg gtg 1581

Phe Thr Cys Ile Ala Ala Asn Ala Ala Gly Glu Ala Thr Ala Met Val

360

365

370

gag gtc tcc atc gtc cag ctg cca cac ctc agc aac agc acc agc cgc 1629

Glu Val Ser Ile Val Gln Leu Pro His Leu Ser Asn Ser Thr Ser Arg

375

380

385

act gca ccc ccc aag tcc cgc ctc tca gac atc act ggc tcc agc aag 1677

Thr Ala Pro Pro Lys Ser Arg Leu Ser Asp Ile Thr Gly Ser Ser Lys

390

395

400

acc agc cgg gga ggt gga ggc agt ggg ggc gga gag cct ccc aaa agc 1725

Thr Ser Arg Gly Gly Gly Gly Ser Gly Gly Gly Glu Pro Pro Lys Ser

405

410

415

420

ccc ccg gaa cgg gct gtg ctt gtg tct gaa gtg acc acc acc tcg gcc 1773

Pro Pro Glu Arg Ala Val Leu Val Ser Glu Val Thr Thr Thr Ser Ala

425

430

435

ctg gtc aag tgg tct gtc agc aag tca gca ccc cgg gtg aag atg tac 1821

Leu Val Lys Trp Ser Val Ser Lys Ser Ala Pro Arg Val Lys Met Tyr

440

445

450

cag ctg cag tac aac tgc tct gac gat gag gta ctg att tac agg atg 1869

Gln Leu Gln Tyr Asn Cys Ser Asp Asp Glu Val Leu Ile Tyr Arg Met

455

460

465

atc cca gcc tcc aac aag gcc ttc gtg gtc aac aac ctg gtg tca ggg 1917

Ile Pro Ala Ser Asn Lys Ala Phe Val Val Asn Asn Leu Val Ser Gly

470

475

480

act ggc tac gac ttg tgt gtg ctg gcc atg tgg gat gac aca gcc acg 1965

Thr Gly Tyr Asp Leu Cys Val Leu Ala Met Trp Asp Asp Thr Ala Thr

485

490

495

500

aca ctc acg gcc acc aac atc gtg ggc tgc gcc cag ttc ttc acc aag 2013

Thr Leu Thr Ala Thr Asn Ile Val Gly Cys Ala Gln Phe Phe Thr Lys

505

510

515

gct gac tac ccg cag tgc cag tcc atg cac agc cag att ctg ggc ggc 2061

Ala Asp Tyr Pro Gln Cys Gln Ser Met His Ser Gln Ile Leu Gly Gly

520

525

530

acc atg atc ctg gtc atc ggg ggc atc atc gtg gcc acg ctg ctg gtc 2109

Thr Met Ile Leu Val Ile Gly Gly Ile Ile Val Ala Thr Leu Leu Val

535

540

545

ttc atc gtc atc ctc atg gtg cgc tac aag gtc tgc aac cac gag gcc 2157

Phe Ile Val Ile Leu Met Val Arg Tyr Lys Val Cys Asn His Glu Ala

550

555

560

ccc agc aag atg gca gcg gcc gtg agc aat gtg tac tcg cag acc aac 2205

Pro Ser Lys Met Ala Ala Ala Val Ser Asn Val Tyr Ser Gln Thr Asn

565

570

575

580

ggc gcc cag cca ccg cct cca agc agc gca cca gcc ggg gcc ccg ccg 2253

Gly Ala Gln Pro Pro Pro Pro Ser Ser Ala Pro Ala Gly Ala Pro Pro

585

590

595

cag ggc ccg ccg aag gtg gtg gtg cgc aac gag ctc ctg gac ttc acc 2301

Gln Gly Pro Pro Lys Val Val Val Arg Asn Glu Leu Leu Asp Phe Thr

600

605

610

gcc agc ctg gcc cgc gcc agt gac tcc tct tcc tcc agc tcc ctg ggc 2349

Ala Ser Leu Ala Arg Ala Ser Asp Ser Ser Ser Ser Ser Ser Leu Gly

615

620

625

agt ggg gag gct gcg ggg ctg gga cgg gcc ccc tgg agg atc cca ccc 2397

Ser Gly Glu Ala Ala Gly Leu Gly Arg Ala Pro Trp Arg Ile Pro Pro

630

635

640

tcc gcc ccg cgc ccc aag ccc agc ctt gac cgc ctg atg ggg gcc ttc 2445

Ser Ala Pro Arg Pro Lys Pro Ser Leu Asp Arg Leu Met Gly Ala Phe

645

650

655

660

gcc tcc ctg gac ctc aag agt cag aga aag gag gag ctg ctg gac tcc 2493

Ala Ser Leu Asp Leu Lys Ser Gln Arg Lys Glu Glu Leu Leu Asp Ser

665

670

675

agg act cca gcc ggg aga ggg gct ggg acg tcg gcc cgg ggc cac cac 2541

Arg Thr Pro Ala Gly Arg Gly Ala Gly Thr Ser Ala Arg Gly His His

680

685

690

tcg gac cga gag cca ctg ctg ggg ccc cct gcg gcc cgg gcc agg agc 2589

Ser Asp Arg Glu Pro Leu Leu Gly Pro Pro Ala Ala Arg Ala Arg Ser

695

700

705

ctg ctc ccc ttg ccg ttg gag ggc aag gcc aaa cgc agc cac tcc ttc 2637

Leu Leu Pro Leu Pro Leu Glu Gly Lys Ala Lys Arg Ser His Ser Phe

710

715

720

gac atg ggg gac ttt gct gct gcg gcg gcg gga ggg gtc gtg ccg ggc 2685

Asp Met Gly Asp Phe Ala Ala Ala Ala Ala Gly Gly Val Val Pro Gly

725

730

735

740

ggc tac agt cct cct cgg aag gtc tcg aac atc tgg acg aag cgc agc 2733

Gly Tyr Ser Pro Pro Arg Lys Val Ser Asn Ile Trp Thr Lys Arg Ser

745

750

755

ctc tct gtc aac ggc atg ctc ttg ccc ttt gag gag agt gac ctg gtg 2781

Leu Ser Val Asn Gly Met Leu Leu Pro Phe Glu Glu Ser Asp Leu Val

760

765

770

ggg gcc cgg ggg act ttt ggc agc tcc gaa tgg gtg atg gag agc acg 2829

Gly Ala Arg Gly Thr Phe Gly Ser Ser Glu Trp Val Met Glu Ser Thr

775

780

785

gtc taggtggggg tgggcatgct ccctttcctg tgcgcagggt gggagaaggg 2882

Val

gaaagaatct cactggcaag tgtttgtgga gtttccatgg tgatgtttac atccaggac 2942

agtttcgtct ccctgtcaat ggctcgtgt cccccctac cccgcaacac ccacatcacc 3002

tccccaccac ccggccgggg tgtgctcagg gaatgtggac tcgctcaaat gccggactga 3062

gccctgagtg tttggaaagg cgagactccg cctttctaata cacaatgta gcctacaagc 3122

aagcggcttt ggattgctta tg 3144

<210> 2

<211> 789

<212> PRT

<213> Homo sapiens

&lt;400&gt; 2

Met Glu Thr Leu

1

Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala Val Val Asp Ala

5

10

15

20

Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu Ser Leu Gly Thr

25

30

35

Leu Cys Pro Ser Lys Gly Leu Leu Phe Val Pro Pro Asp Ile Asp Arg

40

45

50

Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile Ile His Ile Ser

55

60

65

Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp Leu Thr Leu Ser

70

75

80

Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe Leu Asp Leu Glu

85

90

95

100

Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu Pro Ser Leu Gly

105

110

115

Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His Leu Ile Val Asn  
 120 125 130

Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe Glu Asp Phe Leu  
 135 140 145

Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu His Gly Leu  
 150 155 160

Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His Gln Leu Ser Leu  
 165 170 175 180

Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr Phe Ala Asp Leu  
 185 190 195

Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg Leu Gln Lys Leu  
 200 205 210

Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser Ala Leu Thr Ala  
 215 220 225

Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly Gly Asn Pro Leu  
 230 235 240

His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Glu Arg Asp Asp  
 245 250 255 260

Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys Gly Arg Tyr Phe

265

270

275

Trp His Val Arg Glu Glu Glu Phe Val Cys Glu Pro Pro Leu Ile Thr

280

285

290

Gln His Thr His Lys Leu Leu Val Leu Glu Gly Gln Ala Ala Thr Leu

295

300

305

Lys Cys Lys Ala Ile Gly Asp Pro Ser Pro Leu Ile His Trp Val Ala

310

315

320

Pro Asp Asp Arg Leu Val Gly Asn Ser Ser Arg Thr Ala Val Tyr Asp

325

330

335

340

Asn Gly Thr Leu Asp Ile Phe Ile Thr Thr Ser Gln Asp Ser Gly Ala

345

350

355

Phe Thr Cys Ile Ala Ala Asn Ala Ala Gly Glu Ala Thr Ala Met Val

360

365

370

Glu Val Ser Ile Val Gln Leu Pro His Leu Ser Asn Ser Thr Ser Arg

375

380

385

Thr Ala Pro Pro Lys Ser Arg Leu Ser Asp Ile Thr Gly Ser Ser Lys



|   |     |     |     |
|---|-----|-----|-----|
| 390   | 395 | 400 |     |
| Thr Ser Arg Gly Gly Gly Gly Ser Gly Gly Gly Glu Pro Pro Lys Ser |     |     |     |
| 405   | 410 | 415 | 420 |
| Pro Pro Glu Arg Ala Val Leu Val Ser Glu Val Thr Thr Thr Ser Ala |     |     |     |
|   | 425 | 430 | 435 |
| Leu Val Lys Trp Ser Val Ser Lys Ser Ala Pro Arg Val Lys Met Tyr |     |     |     |
|   | 440 | 445 | 450 |
| Gln Leu Gln Tyr Asn Cys Ser Asp Asp Glu Val Leu Ile Tyr Arg Met |     |     |     |
|   | 455 | 460 | 465 |
| Ile Pro Ala Ser Asn Lys Ala Phe Val Val Asn Asn Leu Val Ser Gly |     |     |     |
|   | 470 | 475 | 480 |
| Thr Gly Tyr Asp Leu Cys Val Leu Ala Met Trp Asp Asp Thr Ala Thr |     |     |     |
| 485   | 490 | 495 | 500 |
| Thr Leu Thr Ala Thr Asn Ile Val Gly Cys Ala Gln Phe Phe Thr Lys |     |     |     |
|   | 505 | 510 | 515 |
| Ala Asp Tyr Pro Gln Cys Gln Ser Met His Ser Gln Ile Leu Gly Gly |     |     |     |
|   | 520 | 525 | 530 |

Thr Met Ile Leu Val Ile Gly Gly Ile Ile Val Ala Thr Leu Leu Val

535

540

545

Phe Ile Val Ile Leu Met Val Arg Tyr Lys Val Cys Asn His Glu Ala

550

555

560

Pro Ser Lys Met Ala Ala Ala Val Ser Asn Val Tyr Ser Gln Thr Asn

565

570

575

580

Gly Ala Gln Pro Pro Pro Pro Ser Ser Ala Pro Ala Gly Ala Pro Pro

585

590

595

Gln Gly Pro Pro Lys Val Val Val Arg Asn Glu Leu Leu Asp Phe Thr

600

605

610

Ala Ser Leu Ala Arg Ala Ser Asp Ser Ser Ser Ser Ser Ser Leu Gly

615

620

625

Ser Gly Glu Ala Ala Gly Leu Gly Arg Ala Pro Trp Arg Ile Pro Pro

630

635

640

Ser Ala Pro Arg Pro Lys Pro Ser Leu Asp Arg Leu Met Gly Ala Phe

645

650

655

660

Ala Ser Leu Asp Leu Lys Ser Gln Arg Lys Glu Glu Leu Leu Asp Ser

665

670

675

Arg Thr Pro Ala Gly Arg Gly Ala Gly Thr Ser Ala Arg Gly His His

680

685

690

Ser Asp Arg Glu Pro Leu Leu Gly Pro Pro Ala Ala Arg Ala Arg Ser

695

700

705

Leu Leu Pro Leu Pro Leu Glu Gly Lys Ala Lys Arg Ser His Ser Phe

710

715

720

Asp Met Gly Asp Phe Ala Ala Ala Ala Ala Gly Gly Val Val Pro Gly

725

730

735

740

Gly Tyr Ser Pro Pro Arg Lys Val Ser Asn Ile Trp Thr Lys Arg Ser

745

750

755

Leu Ser Val Asn Gly Met Leu Leu Pro Phe Glu Glu Ser Asp Leu Val

760

765

770

Gly Ala Arg Gly Thr Phe Gly Ser Ser Glu Trp Val Met Glu Ser Thr

775

780

785

Val

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an  
artificially synthesized primer sequence.

<400> 3

gactagttct agatcgcgag cggccgccct tttttttttt tttt

44

<210> 4

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an  
artificially synthesized adapter sequence.

<400> 4

tcgacccacg cgtccg

16

<210> 5

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an  
artificially synthesized adapter sequence.

<400> 5

cggacgcgtg gg

12

<210> 6

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an  
artificially synthesized primer sequence.

<400> 6

cagggtggga gaaggggaaa gaatc

25

<210> 7

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an  
artificially synthesized primer sequence.

<400> 7

gaggccattg acagggagac gaaac

25

**COMBINED DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN, the specification of which:

- ☐ is attached hereto.  
☒ was filed on May 15, 2001 as Application Serial No. 09/831,846 and was amended on \_\_\_\_\_.  
☐ was described and claimed in PCT International Application No. \_\_\_\_\_ filed on \_\_\_\_\_ and as amended under PCT Article 19 on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

| Country | Application No. | Filing Date       | Priority Claimed  |
|---------|-----------------|-------------------|---|
| PCT     | PCT/JP99/06449  | November 18, 1999 | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Japan   | 10/331727       | November 20, 1998 | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Janis K. Fraser, Ph.D., J.D., Reg. No. 34,819  
 J. Peter Fasse, Reg. No. 32,983  
 Anita L. Meiklejohn, Reg. No. 35,283

John W. Freeman, Reg. No. 29,066  
 Timothy A. French, Reg. No. 30,175  
 Ralph A. Mittelberger, Reg. No. 33,195

(6)

Address all telephone calls to JANIS K. FRASER, PH.D., J.D. at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER, PH.D., J.D. at:

FISH & RICHARDSON, P.C.  
225 Franklin Street  
Boston, MA 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

→

**Combined Declaration and Power of Attorney**

Page 2 of 3 Pages

1-00  
Full Name of Inventor: SHIN-ICHI FUNAHASHI

Inventor's Signature: Shin-ichi Funahashi Date: Aug 1, 2001  
Residence Address: Ibaraki, Japan  
Citizenship: Japan JPX  
Post Office Address: c/o Tsukuba Research Laboratory  
Chugai Seiyaku Kabushiki Kaisha  
153-2 Nagai, Niihari-mura, Niihari-gun  
Ibaraki 300-4101 Japan

2-00  
Full Name of Inventor: SHIOJI MIYATA

Inventor's Signature: Shoji Miyata Date: Aug 1, 2001  
Residence Address: Ibaraki, Japan  
Citizenship: Japan JPX  
Post Office Address: c/o Chugai Research Institute for Molecular Medicine, Inc.  
153-2, Nagai, Niihari-mura, Niihari-gun  
Ibaraki 300-4101 Japan

3-00  
Full Name of Inventor: NOBUO NOMURA

Inventor's Signature: Nobuo Nomura Date: 8/9/2001  
Residence Address: Chiba, Japan  
Citizenship: Japan JPX  
Post Office Address: 5-2-11, Hachimandai, Kisarazu-shi  
Chiba 292-0814 Japan

4-00  
Full Name of Inventor: TAKAHIRO NAGASE

Inventor's Signature: Takahiro Nagase Date: 8/6/2001  
Residence Address: Chiba, Japan  
Citizenship: Japan JPX  
Post Office Address: c/o KAZUSA DNA RESEARCH INSTITUTE  
1532-3, Yana, Kisarazu-shi  
Chiba 292-0812 JAPAN

→



**Combined Declaration and Power of Attorney**

Page 3 of 3 Pages

5-00

Full Name of Inventor: OSAMU OHARA

Inventor's Signature: Osamu Ohara Date: August 6, 2001

Residence Address: Chiba, Japan


Citizenship: Japan

Post Office Address: c/o KAZUSA DNA RESEARCH INSTITUTE  
1532-3, Yana, Kisarazu-shi  
Chiba 292-0812 JAPAN

20271076.doc

20271076.doc

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☑ Scanned copy is best available. Drawings figure 1 and 2 are  
dark.